



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

## Automation in the life science research laboratory

**Citation for published version:**

Holland, I & Davies, JA 2020, 'Automation in the life science research laboratory', *Frontiers in Bioengineering and Biotechnology*. <https://doi.org/10.3389/fbioe.2020.571777>

**Digital Object Identifier (DOI):**

[10.3389/fbioe.2020.571777](https://doi.org/10.3389/fbioe.2020.571777)

**Link:**

[Link to publication record in Edinburgh Research Explorer](#)

**Document Version:**

Peer reviewed version

**Published In:**

Frontiers in Bioengineering and Biotechnology

**General rights**

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



1 We request our article to be submitted in British English.

## Automation in the life science research laboratory

2 **Ian Holland<sup>1\*</sup>, Jamie A. Davies<sup>1</sup>,**

3 <sup>1</sup> Deanery of Biomedical Science & Synthesis Centre for Synthetic & Systems Biology, University of  
4 Edinburgh, George Square, Edinburgh, EH8 9XB, United Kingdom.

5 **\* Correspondence:**

6 Ian Holland

7 iholland@exseed.ed.ac.uk

8 **Keywords: laboratory automation, life science research, automation design, research efficiency,**  
9 **reproducibility, innovation inhibition, environmental design**

### 10 **Abstract**

11 Protocols in the academic life science laboratory are heavily reliant on the manual manipulation of  
12 tools, reagents and instruments by a host of research staff and students. In contrast to industrial and  
13 clinical laboratory environments, the usage of automation to augment or replace manual tasks is  
14 limited. Causes of this 'automation gap' are unique to academic research, with rigid short-term  
15 funding structures, high levels of protocol variability and a benevolent culture of investment in  
16 people over equipment. Automation, however, can bestow multiple benefits through improvements in  
17 reproducibility, researcher efficiency, clinical translation, and safety. Less immediately obvious are  
18 the accompanying limitations, including obsolescence and an inhibitory effect on the freedom to  
19 innovate. Growing the range of automation options suitable for research laboratories will require  
20 more flexible, modular and cheaper designs. Academic and commercial developers of automation  
21 will increasingly need to design with an environmental awareness and an understanding that large  
22 high-tech robotic solutions may not be appropriate for laboratories with constrained financial and  
23 spatial resources. To fully exploit the potential of laboratory automation, future generations of  
24 scientists will require both engineering and biology skills. Automation in the research laboratory is  
25 likely to be an increasingly critical component of future research programs and will continue the  
26 trend of combining engineering and science expertise together to answer novel research questions.

### 27 **1 Introduction**

28 The progressive integration of automation into work environments has enhanced the production rates,  
29 efficiency and quality of an enormous array of industrial processes (Hitomi 1994; Autor 2015). From  
30 generation to generation, mechanised tooling has replaced swathes of manual tasks. More recent  
31 advances in robotics and information technology have further automated processes that were once the  
32 sole domain of human brawn or brain (Hasegawa 2009). Life science research conducted within  
33 academic institutions has also welcomed the ingress of mechanised equipment designed to automate  
34 a range of tasks. However, it is noticeable that a typical university research laboratory, often led by a  
35 single principal investigator, maintains a high level of manual manipulation in the form of  
36 undergraduate, postgraduate, post-doctoral and technical staff. Many experimental procedures remain  
37 heavily reliant upon the individual researcher manually carrying out protocols at the research bench.

38

39 This is in contrast to industrial environments, where widespread investment in automation has  
40 allowed companies to maximise their outputs and increase profits (Ravazzi and Villa 2009).  
41 Laboratories in a clinical setting have also experienced the benefits of adopting automation (Hawker  
42 et al. 2017), increasing the speed and reliability of patient-specific data for use by clinicians (Lou et  
43 al. 2016; Sarkozi et al. 2003). In this review, written from the perspective of an automation engineer  
44 now working in synthetic biology research and a Principal Investigator managing a research  
45 laboratory, we classify the current levels of automation in laboratories and highlight the benefits and  
46 limitations of its usage in research. We further attempt to summarise why automation has had such a  
47 limited impact in our workplace (Jessop-Fabre and Sonnenschein 2019) and ask whether the solution  
48 to including more automation into everyday laboratory tasks may reside in greater communication  
49 between scientists and engineers. Further, we suggest that it could be accelerated by beginning with a  
50 more low-tech approach rather than striving too soon for fully autonomous systems.

## 51 **2 Current laboratory automation**

52 Well-meaning predictions of the cybernetic laboratory (Beugelsdijk 1991) and a robotic revolution  
53 (Boyd 2002) have, at the time of writing, yet to materialise in the majority of life science research  
54 laboratories. Evidence from the proportional use of the terms “automation” or “automated” in the  
55 titles of PubMed listed articles does, however, exhibit a steady increase over the previous 4 decades.  
56 The terms “robot” or “robotic”, which are often used interchangeably with automation, received  
57 negligible use until the mid 90’s and then showed a more marked elevation (Figure 1). It should be  
58 noted however that, “robot” or “robotic” can also be used as an adjective for biological systems or  
59 medical devices and the increase in their prevalence may represent changes in language usage rather  
60 than an indication of greater automation usage. A more thorough text mining exercise than ours  
61 attempted to measure the extent of manual protocols that could potentially be automated through  
62 analysis of methods sections in published life science articles. The study concluded that 89% of  
63 articles featured a manual protocol that has an automated alternative (Groth and Cox 2017). Whilst  
64 there is a scale of automation, from the simple to the complex, that could be applied to these  
65 protocols, such data provides evidence that there remains a large potential for automation in most  
66 biology research laboratories. There are also clear claims in the literature that researchers working in  
67 academic institutions have been slow to embrace automation (Jessop-Fabre and Sonnenschein 2019;  
68 De Almeida and Ferreira 2017; Sadowski et al. 2016).

69 In this review we focus on automation where it describes equipment that physically manipulates  
70 items and we do not consider solely software-based technologies, such as image analysis and data  
71 mining tools. Within our scope there resides a diverse range of equipment that is found in research  
72 laboratories, from simple hand tools to entirely autonomous systems. A classification system for  
73 laboratory automation equipment has, to our knowledge, yet to be published, although a number of  
74 equivalent methods have been developed for classifying industrial automation. Frohm et al, reviewed  
75 these systems before proposing their own 7 levels of automation (Frohm et al. 2008). These levels  
76 and descriptions are displayed in table 1, alongside examples typically seen in an academic research  
77 laboratory, and an indicative cost.

78

79 It is noticeable from table 1 that the majority of equipment items that researchers would consider as  
80 the most expensive in their laboratory are categorised at level 5. Higher grade 6 and 7 items are a  
81 rarity in a biological research laboratory. Whilst mid-range level 5 automation items undoubtedly  
82 increase the efficiency of laboratory research, they are designed for specific subtasks in a range of  
83 protocols. These items also generally require a large amount of manual manipulation both before and  
84 after machine usage. Within the research laboratory this category of equipment is commonplace and  
85 dominates equipment budgets. A further observation can be made in that the majority of research  
86 equipment in this category performs tasks that human operators would otherwise be incapable of  
87 carrying out themselves (McClymont and Freemont 2017). The rotation of samples at high speeds  
88 and observing microscale environments are examples of tasks that would be impossible without the  
89 use of centrifugation and microscopy equipment. Automation equipment which replaces manual  
90 handling tasks is rarer, and it the prevalence of these items where academic bioresearch facilities  
91 differ to industrial environments and clinical laboratories.

92 Access to high level 7 automated equipment can usually only be obtained through a pooled resource  
93 shared between across the parent organisation or wider research community; these are often referred  
94 to as biofoundries (Chambers et al. 2016; Chao et al. 2017; Kitney et al. 2019). A new automation  
95 variant of the commercial contract research organisation has also arisen recently, the cloud lab. These  
96 provide researchers with remote access to heavily automated protocols available as a pay-per-  
97 experiment service (Hayden 2014). Cloud lab executives have made grand predictions regarding the  
98 impact these facilities will have on the future of biological research (Segal 2019; Miles and Lee  
99 2018), although doubts remain regarding experimental flexibility and the resulting inhibitory effect  
100 on experimental innovation (Hayden 2014).

## 101 **3 Benefits of laboratory automation**

### 102 **3.1 Reproducibility**

103 There are multiple advantages and limitations in including automation into scientific processes and  
104 these are summarised in figure 2. Most pertinent is its use in improving the reproducibility of  
105 laboratory research (Kitney et al. 2019). Reproducibility is a major concern for the research  
106 community both now (Baker 2016; Begley and Ioannidis 2015) and historically (reviewed by Fanelli  
107 2018), with associated economic implications (Freedman, Cockburn, and Simcoe 2015) and an  
108 undermining of public trust in science (Saltelli and Funtowicz 2017). Debate continues regarding the  
109 definition and scope of the reproducibility issue (Goodman, Fanelli, and Ioannidis 2018; Casadevall  
110 and Fang 2010), alongside proposed improvements in scientific practices (Munafò et al. 2017; Peng  
111 2015) and remedial technologies (Benchoufi and Ravaud 2017). Increasing the use of automation  
112 throughout research laboratories is one such proposition (Jessop-Fabre and Sonnenschein 2019;  
113 Kitney et al. 2019). An improvement in reproducibility is cited as a beneficial effect of automation  
114 implementation within clinical laboratories (Genzen et al. 2018; Hawker et al. 2017).

115 Automation can assist in improving reproducibility in three ways: a reduction in human-induced  
116 variability, an increase in the rate of data generation, and a decrease in contamination. The  
117 contribution each of these factors has on increasing reproducibility depends on the individual  
118 protocol. Firstly, experimental variability caused by humans is an omnipresent day-to-day reality in  
119 research laboratories (Plebani 2010; Price et al. 2015). Variation in protocols can arise from the same  
120 person unknowingly performing a task differently each time or between different individuals  
121 attempting to carry out the same procedure. Variability that is noticed at the time can be corrected for  
122 with repeated protocols or experimental redesign, although with an associated time penalty.

123 However, variation that goes unnoticed will manifest itself in final datasets and published results.  
124 Automation can replace many, but not all, of these human-based sources of variability. Mechanised  
125 componentry is more suited to repetitive tasks (Moutsatsou et al. 2019) in comparison to humans  
126 who are vulnerable to progressive mental fatigue (Xu et al. 2018), physical weariness (Iridiastadi and  
127 Nussbaum 2006; Björklund et al. 2000) and also distracting influences (Varao-Sousa et al. 2018).  
128 Laboratory protocols where manual operations have been automated demonstrate greater consistency  
129 in their results, improving experimental reproducibility (Klevebring et al. 2009; Price et al. 2015).  
130 Secondly, a greater rate of experimental data capture, with an increased volume of results, can be  
131 achieved with automation alongside a wider range of experimental variables tested, including  
132 controls. Ultimately this increases the likelihood that others will be able to reproduce and build on  
133 their findings (Maleki et al. 2019). Finally, there are those laboratory protocols that are susceptible to  
134 contamination that can arise from either from the researchers themselves (Salter et al. 2014) or  
135 through increased exposure to environmental contaminants due to ponderous manual handling  
136 operations (Greub et al. 2016). Automation can remove contact with human operators (Wilke et al.  
137 1995) or reduce potential contaminant exposure by lowering the required number of manual handling  
138 steps (Mifflin, et al. 2000; Moutsatsou et al. 2019).

### 139 **3.2 Laboratory efficiency**

140 Efficiency is considered of paramount importance within manufacturing and can be defined as the  
141 rate of production, divided by the resources such as labour, input materials needed to accomplish this  
142 rate. By investing in automation, a company can increase the rate of production and also reduce the  
143 resources needed to achieve this rate. With a market available this can translate to a corresponding  
144 increase in profits (Ceroni 2009). A research laboratory investing in automation can improve the  
145 efficiency of its researchers (Hawker and Schlank 2000; Schneider 2018) with machinery able to  
146 achieve a greater rate of experimental output than a manual based alternative (Tacker et al. 2014;  
147 Choi et al. 2018; Price et al. 2015). It should be noted that an automated protocol need not take less  
148 time from start-to-finish to result in higher output than the manual alternative, as long as it demands  
149 less human intervention (Reed et al. 2018). This is due the to the reward for academia differing from  
150 industry, with efficiency considered more as a time input to experimental output ratio. The key  
151 benefit derived from laboratory automation driven processes is therefore in the time saved by the  
152 researchers; time that can be spent on other parallel experiments. Automation in most cases will  
153 induce a transition from manual to cognitive labour (Kaber et al. 2009). Allowing an operator to set a  
154 protocol in operation and walk away to think and focus on other tasks is a valuable function for any  
155 automation equipment. Researchers frequently have multiple projects, and experimental protocols  
156 operating in parallel as well as an array of responsibilities beyond the laboratory. With a greater rate  
157 of automation-driven experimental output researchers can also identify which aspects of their  
158 experiments don't work and adjust more quickly (Baranczak et al. 2017). Within industrial  
159 pharmaceutical development this methodology is known as fail fast, fail often (Clark and Pickett  
160 2000; Besteman and Bont 2019; Khanna et al. 2016). Efficiency gains can also extend to the use of  
161 expensive reagents and materials. Automation can provide a higher level of precision in reagent  
162 dispensing, reducing the amount needed per experiment.

### 163 **3.3 Faster translation**

164 Automation has an important role in those laboratories engaged in applied research who are seeking  
165 to develop novel therapeutic interventions such as cell-based therapies, pharmaceutical developments  
166 or tissue-engineered constructs for implantation. Transition of these technologies from a purely  
167 research domain to final usage in a clinical setting is frequently difficult (Hua et al. 2018; Ochs et al.

168 2017), often referred to as translation from the bench to the bedside (Goldblatt and Lee 2010). By  
169 considering and including automation at an early stage in the research process, crucial elements of  
170 the process can be mechanised, increasing product quality and production rates in the laboratory  
171 before the jump to manufacturing. The technological leap from laboratory-scale production to higher-  
172 volume manufacturing is therefore shortened. Researchers who include automation technologies at an  
173 early stage are subsequently better placed to upscale their processes allowing faster  
174 commercialisation rates and deployment to the clinic (Kotin 2011; Rafiq and Thomas 2016;  
175 Heathman et al. 2015).

### 176 3.4 Safety

177 A number of protocols carried out in the research laboratory require the handling of dangerous  
178 reagents and occasionally of hazardous tooling. The manual manipulation of hazardous items places  
179 a burden on laboratories, particularly when contending with a continual turnover of short-term  
180 contract staff and students who require safety training and supervision. By assigning dangerous  
181 handling tasks to automated machinery, the exposure of humans to hazardous substances can be  
182 reduced (Movsisyan et al. 2016; Caragher et al. 2017).

### 183 3.5 Examples of automation benefits

184 Evidence of automation benefits can be observed in recent success stories. In scenarios where high-  
185 throughput, reproducible results are demanded over short time frames automation has a significant  
186 advantage over manual based procedures. Recently a highly automated biofoundry, normally with a  
187 focus on research applications, was repurposed towards the development of SARS-CoV-2 assays for  
188 clinical diagnostics (Crone et al. 2020). Automated liquid handling equipment and was able to  
189 perform an extensive array of experimental procedures at a rate in excess of those that a manual  
190 based laboratory could carry out. Furthermore, in these time pressured experiments automation has  
191 an advantage over manual operators who are likely to be prone to fatigue and errors, with an  
192 associated negative effect on reproducibility. Such work also clearly demonstrates the positive impact  
193 automation can have on novel public health challenges. It also an example where considerate design  
194 has led to systems that are flexible enough to be rapidly adapted to meet new experimental needs,  
195 appropriately termed “facility agility”.

196 The use of automation to improve research efficiency has also been shown with the publication of a  
197 system comprising a mobile robotic platform that can autonomously navigate a laboratory  
198 performing reagent dispensing and handling operations at a range of experimental benchtop stations  
199 (Burger et al. 2020). In combination with an artificial intelligence search algorithm the system was  
200 able to focus on reagent combinations deemed more likely to provide an optimum result. The  
201 capacity of the robotic equipment to operate at all hours, with pausing only to charge batteries,  
202 allowed it to ascertain answers to 5 experimental hypotheses in a fraction of the time a manual  
203 research team would have required. Although used to answer a research question within a chemistry  
204 context the concept is readily applicable to life science experimental laboratories. The system shares  
205 similar liquid and solid reagent handling operations to a life science laboratory as well as the  
206 common challenge whereby multiple variables create a research space too great for manual  
207 researchers to reasonably explore. A further crucial advantage of this arrangement resides in the  
208 capability, with appropriate safety controls, to allow a laboratory to operate as a hybrid manual-  
209 automated laboratory, potentially with a peopled day shift followed by a robotic night shift.

210 The translation of stem cell derived therapies towards a clinical application has received automation  
211 attention in a range of projects. Such therapies will ultimately require the expansion of stem cells on

212 a scale that is beyond manual based laboratories, with large numbers also needed for research and  
213 clinical trials phases. The need for reliable methods of high-volume, quality assured cells has led to  
214 the development of automated systems such as the StemCellFactory (Doulgkeroglou et al. 2020),  
215 StemCellDiscovery (Jung et al. 2018) and AUTOSTEM (Ochs et al. 2017). The objective of these  
216 systems is to automate the normally manual stages of stem cell seeding, growth, colony selection,  
217 passaging, quality assessment, harvesting and potentially in later applications differentiation. In a  
218 similar fashion to the previous mobile robotic platform example complex control algorithms are also  
219 being applied to these systems with the aim of improving usable cell yields (Egri et al. 2020). These  
220 projects are an important link between the domains of basic life science research, clinical application  
221 and also commercial cell product manufacturing. By developing these systems researchers have been  
222 able to generate high quantities of cells for research and testing purposes, hastening the route to  
223 clinical usage.

224

## 225 **4 Limitations of automation**

### 226 **4.1 Incorrect application**

227 Despite the range of benefits that laboratory automation can bring, there remains a number of  
228 limitations. Integrating automation into a research laboratory is not in itself a guarantee of success  
229 and, where applied incorrectly can even result in even less efficiency (Zielinski et al. 2014). The  
230 nature of automated tasks also allows for rapid propagation of errors. An example would be a  
231 machine incorrectly dispensing a reagent repetitively which can then, if undetected, be distributed  
232 across many thousands of samples. In addition, the incorrect application and operation of automation  
233 may not improve the reproducibility of research between laboratories. Automation machinery  
234 carrying out the same experimental protocol in different laboratories may still produce different  
235 results. This can be due to variations in input materials, different equipment models or set-up and  
236 calibration errors. Even where automation has been carefully integrated into a laboratory and has  
237 demonstrated an improvement in reproducibility an inherent machine to machine variability can  
238 remain. What is more, this variability can be more hidden than more easily observed manual  
239 procedures. Careful maintenance, calibration and quality control measures are therefore essential in  
240 implementing any laboratory automation system (Xie et al. 2004; Hawker and Schlank 2000).

### 241 **4.2 Obsolescence**

242 Obsolescence is an inevitability for any technology and even, it can be argued, for scientists  
243 themselves. Many facilities will feature a dusty machine in the corner that is unused, because  
244 components and materials are no-longer available, the protocol itself has been supplanted or simply  
245 newer more effective equipment has taken over (Croxatto et al. 2016). Predicting how and when a  
246 machine will become obsolete is an inherently difficult task in rapidly evolving research fields and  
247 can be specific to individual laboratories. Some researchers will find equipment is no-longer useful  
248 after a few years of operation whilst others may continue to happily use the same machine for  
249 decades. It is not only advances in hardware and software design that can render laboratory  
250 equipment obsolete. Scientific progress in reagent properties and resulting modifications to protocols  
251 can also be responsible. The advent of new thermostable polymerases obsoleted a whole generation  
252 of Polymerase Chain Reaction machinery designed upon a more repetitive protocol (Hawker et al.  
253 2017). Despite these difficulties, with considerate design allowing for reconfiguration and  
254 modification premature obsolescence can be delayed (Crombie et al. 2017; Harrison et al. 2007),

255 referred to in some industries as future-proofing. Understanding and planning for obsolescence is  
256 therefore an important part of any automation strategy.

### 257 **4.3 Innovation inhibition**

258 There is a danger that automation can inhibit creativity in the experimental design process by limiting  
259 the opportunities for changing or tinkering with a protocol. A researcher may be less inclined to alter  
260 a protocol to optimise it for a new situation where a large number of steps are automated. This can be  
261 based upon the assumption that process steps carried out by machinery are already optimised and  
262 require no further improvement. They may also feel less able to begin changing things because they  
263 lack the confidence or maybe even the authorisation to open the box and begin modifying what is  
264 probably an expensive machine. Sharing of the machine with other users for whose purposes it is  
265 already optimised is also a brake to experimentation with parameters. Innovation inhibition is also a  
266 concern where protocols are outsourced to third party automated laboratories (Hayden 2014).

### 267 **4.4 Workforce impact**

268 When integrating new automation into any workplace environment, the impact on workers and how  
269 they view new machinery must be carefully considered. Beginning in the rural English midlands with  
270 the machine breaking Luddite movement (Roberts 2017), societal resistance to automated machinery  
271 replacing manual labour and the threat it poses to livelihoods understandably continues into the  
272 present day (Jones 2013; Autor 2015). Both positive and negative reactions to the introduction of  
273 automation have been observed amongst long-term workers in clinical laboratory settings (Thomson  
274 and McElvania 2019) and it is reasonable to anticipate that similar reactions may arise in research  
275 laboratories. The outright replacement of researchers by automation is unlikely as they are currently  
276 categorised as being amongst the lowest risk of being replaced (White, et al. 2019), due to their  
277 breadth of skills, including planning and creativity (Reeves et al. 2019). However, researchers solely  
278 employed to perform repetitive manual tasks are more at risk and thus more likely to view  
279 automation as a threat. Those researchers with a multitude of other protocols and tasks beyond the  
280 laboratory are more likely to view automation assistance in their day to day roles in a positive  
281 manner. The short-term contracts that predominate in research will also lessen any hostility to  
282 automation. Employees who understand that they will be moving on to another position, will see a  
283 machine as more likely to be a replacement for their replacement rather than a replacement for  
284 themselves. Although the levels of militancy advocated by the early Luddites may not be repeated,  
285 laboratory managers who introduce automation will still, like their industrial and clinical  
286 counterparts, need to be sensitive to workforce reactions, particularly the impact on any long-term  
287 employees.

### 288 **4.5 Automation hyperbole**

289 Both vendors of automation equipment and researchers must also be wary of overstating the benefits  
290 of automation and elevating expectations regarding the impact its introduction will have on future  
291 work practices. Automation hyperbole and the accompanying benefits is however part of a wider  
292 trend that is not only restricted to research (Wajcman 2017). Whilst automation can improve protocol  
293 reproducibility and efficiency the individual researcher will, in the majority of cases, still be  
294 responsible for correctly operating the equipment, with maintenance, quality of input materials, and  
295 calibration. These are tasks than can require a high level of personal discipline and tenacity. With  
296 notable exceptions (King et al. 2009; Williams et al. 2015), automation will also be unable to  
297 undertake the overall experimental design and analysis. Journal publications have a responsibility  
298 too, to ensure that articles advocating laboratory automation equipment also highlight the limitations



299 of their technologies, as well as identifying author conflicts of interests (Miles and Lee 2018).  
300 Greater awareness of limitations will allow more effective matching of automation solutions with  
301 laboratory problems and increase the trust between commercial vendors and academic institutions.

## 302 **5 Laboratory automation obstacles**

### 303 **5.1 Automation is expensive and difficult to justify**

304 The most significant hurdle for PIs wishing to integrate automation systems into their laboratories is,  
305 unsurprisingly, cost. Commercially available automation equipment is expensive, whilst bespoke  
306 equipment for individual protocols costlier still. Cell culture is an example of a common, labour-  
307 intensive protocol familiar to generations of researchers. Equipment to automate cell culture is  
308 available and can save many hours of researcher effort from the process, but is tantalisingly out of  
309 reach for most laboratories. The cost of these items can be in excess of \$1M for a complete process  
310 system (Storrs 2013) placing them far beyond the reach of the majority of academic laboratories.  
311 Despite being commercially available for over 18 years (Kempner and Felder 2002) they remain a  
312 rare sight in research environments but are used in high volume cell-banking organisations (Wrigley  
313 et al. 2014; Daniszewski et al. 2018; Archibald et al. 2016).

314 The development of automation equipment can be a time-consuming and expensive process. Initial  
315 rounds of iterative conceptual and prototype design and testing are followed by final design, build,  
316 and commissioning phases. Coordination is needed from a variety of disciplines including  
317 mechanical, electrical and software engineers alongside close collaboration with the end user. Most  
318 important for all automation projects however, is a source of capital investment. Industrial investment  
319 in automation is matched to business cases in which increasing confidence in the product and the  
320 associated income from projected sales is used to justify upfront capital expenditure. However, an  
321 academic principal investigator seeking to invest in automation for their laboratory is confronted by a  
322 different set of challenges. When compared to industrial and commercial organisations, a research  
323 laboratory's output or success rate cannot be measured in using the same readily quantifiable metric  
324 of profit. Indeed, academic research output has long been a difficult entity to define both for  
325 individual researchers (Klaus and Alamo 2018) and laboratories (Abramo and D'Angelo 2014;  
326 Kreiman and Maunsell 2011). It is therefore more difficult to construct a 'business' case when  
327 seeking funding for laboratory automation equipment. A factory manager is able to justify a new item  
328 of automation based upon the argument that whilst it may initially cost X units of currency it will  
329 increase profits by X+Y units, measured in the same currency (Ceroni 2009). A clinical laboratory  
330 manager can present a similar case based upon both cost (Archetti et al. 2017; Sarkozi, et al. 2003)  
331 and the quantifiable output of turnaround time (Hawkins 2007; Archetti et al. 2017). A research  
332 laboratory manager however, in the same position applying for funding, will have greater difficulty  
333 in arguing that although the proposed equipment will cost X units of currency it will increase their  
334 laboratory's research output by Y vaguely defined research outputs. The ambiguity of research  
335 success hinders laboratories seeking to invest in automation.

### 336 **5.2 Research funding structures**

337 The allocation of scientific funding to academic institutions further limits investment in automation.  
338 Research programs are most frequently funded through externally sourced grants that are applied for  
339 in a competitive environment, with pre-applied constraints on the amounts available and where these  
340 funds may be spent. Understandably the majority of funding calls open to scientific laboratories are  
341 seeking answers to novel scientific questions and not looking to develop items of equipment that are  
342 essentially engineering challenges. Should an applicant wish to include standard or bespoke

343 automation when applying for grants, capital expenditure on large equipment, if even permitted, must  
344 be explicitly accounted for before the project starts. Unfortunately, the nature of research means that  
345 the details of protocols needed for the project are not always available during the early proposal  
346 phase. Estimating the both the timescales and cost of automation at such an early stage is a difficult  
347 task for supervisors of biological research laboratories who will have limited experience of budgeting  
348 for automation hardware. The time duration of funding grants also limits the development of  
349 automation, usually with the maximum being 5 years (Vaesen and Katzav 2017; European  
350 Commission 2016). Automation strategies for industry are generally greater in duration and aligned  
351 to the anticipated lifecycle of the product, frequently extending into decades. In the case of  
352 commercialising a novel pharmaceutical product or medical device the automation strategy can be  
353 aligned to the 20-year exclusivity patent window. Automation expertise acquired over this time can  
354 then be exploited to maintain a competitive advantage when the window expires. Academic projects  
355 of a comparable length are rare. The Human Genome Project is one exception, and consequently was  
356 able to invest and substantially benefit from automation (Meldrum 2000). However, long-term,  
357 project specific funding stability is rarely available to most academic principal investigators, limiting  
358 automation investment.

359 Short-term research funding also places a limit on the individual researcher's ability to develop  
360 automation. Hands-on researchers are best placed to determine which elements of their protocols  
361 would benefit from automation. However, these individuals are typically PhD students or early career  
362 researchers with a time-limited contract or project. Such temporal limitation leaves little room for  
363 developing an idea for protocol automation into a functional system, particularly with specific  
364 scientific targets attached to the grant scheme funding their project. Short duration research positions  
365 reduce not only the time available to develop novel automated laboratory equipment but also the  
366 motivation for doing so. On completion, a researcher is likely to move on to a new laboratory  
367 contract or a career beyond academia (van der Weijden et al. 2016). Researchers are therefore  
368 unlikely to experience any of the long-term benefits from planning automation. The cumulative effect  
369 of short-term, competitive grant allocations and transient researchers creates an environment unsuited  
370 to the long-term financial investment required for laboratory automation development.

371 A limited number of large grant funded projects have been successful in devising automation  
372 strategies and equipment, although often with a focus on industrial scale systems for clinical  
373 translation rather than research laboratories. One area that seen recent attention is the [aforementioned](#)  
374 development of high-volume manufacturing solutions for the production of Mesenchymal and  
375 Induced Pluripotent Stem Cells to meet anticipated future clinical demand (Rafiq et al. 2016; Jossen  
376 et al. 2018; Panchalingam et al. 2015; Ochs et al. 2017; Marx et al. 2013). It is hoped that technology  
377 developed in these programs will, in the future, trickle down into more affordable systems that can be  
378 exploited by smaller research laboratories.

### 379 **5.3 Stifled commercial development of new laboratory automation**

380 Financial challenges also hinder those commercial organisations seeking to develop laboratory  
381 automation equipment. Industrial automation design and development is often a bespoke,  
382 collaborative arrangement for a particular challenge. A manufacturer will approach one or more  
383 automation developers to design a manufacturing system for their product. In this scenario the  
384 manufacturer is usually a much larger organisation with abundant reserves of capital and will also  
385 carry the majority of the risk should the product not sell as well as expected. To aid in mitigating this  
386 risk they are able to utilise their marketing, sales and distribution expertise within their particular  
387 market sector. For development of automated laboratory equipment, the scenario is often different.

388 An automation developer may wish to partner with an academic research laboratory. However, as  
389 previously detailed, in such an arrangement the laboratory will be unable to operate as a cash-rich  
390 development partner unless a substantial funding grant can be obtained. The automation developer  
391 must therefore carry the risk that the equipment will not be commercially successful and assume the  
392 role of marketing and selling the product to the wider research community. Biological laboratories  
393 are best placed to identify where certain processes would benefit from automation, but don't have the  
394 financial resources or expertise to develop these systems themselves. Automation companies, whilst  
395 having the capable expertise to develop automation equipment will be reluctant to pursue such a  
396 business strategy requiring up-front investment to develop a product for customers widely  
397 acknowledged to have little disposable capital.

398 Small-to medium-sized automation companies have often been most successful at innovative  
399 development of laboratory equipment, funded through grant schemes in cooperation with an  
400 academic institution or external venture capital funding. Examples include benchtop pipetting  
401 systems from Andrew Alliance and OpenTrons and Labman automation's formulation engine.  
402 Access to joint research grants and funding schemes can encourage the development of novel  
403 automation solutions by increasing industrial and academic collaboration whilst also reducing the  
404 risk the commercial risk that developers are exposed to.

#### 405 **5.4 Laboratory space**

406 Alongside the financial investment required for automation researchers must also find physical  
407 laboratory space for new equipment, incurring a footprint cost (Wong et al. 2018; Moutsatsou et al.  
408 2019). The size and mass of many automation items means that it is not always practical or safe to  
409 tidy the item away and store it when it is not required. Laboratory space is often at a premium in  
410 many research institutions with territorial researchers often coming into conflict over the allocation of  
411 it (Adams 2004). A bench occupied by equipment is also an area that could be otherwise be utilised  
412 by productive researchers. The requirement for some laboratories to operate as a dual research and  
413 teaching environment further constrains the available space. It may also not be possible for  
414 automation to totally replace more manual based equipment and space in laboratories, with room  
415 required for both. The need to maintain cell culture hoods for teaching is one example. Developers of  
416 laboratory of automation have attempted to minimise the footprint of their machinery through  
417 innovative reworkings of traditional laboratory procedures. The use of hollow fibre arrays (Russell et  
418 al. 2018) and multi-axis liquid and labware manipulation (Kato et al. 2010) are examples of compact  
419 automated adherent cell culture systems. Spatial constraints may push future bench-based laboratory  
420 automation towards an architectural style resembling inner city skyscrapers.

#### 421 **5.5 Protocol variation and usage**

422 The very nature of bioresearch involves the design and implementation of protocols aimed at the  
423 determining answers to novel research questions. In pursuit of these targets, researchers will devise  
424 new protocols or substantially modify existing ones to suit their needs. Recurring cycles of method  
425 generation and evolution within the research laboratory create a high-level of protocol variation that  
426 is not always easily automated. Matching commercially available automation equipment to these  
427 requirements is often not a feasible option with fixed componentry and locked-in software frequently  
428 being the limiting factors. Automated cell culture is an example where the available systems can be  
429 insufficiently flexible to accommodate the specific cell culture requirements of an individual  
430 laboratory (Crombie et al. 2017), with some requiring a broad range of cell culture types and others  
431 having more focussed needs. A high level of experimental process variation is therefore more likely  
432 to require a bespoke automation system, the development of which will have an associated time and

433 financial cost. Clinical laboratories, by comparison, have a greater level of consistency across  
434 protocols both within individual laboratories and across institutions, contributing to the widespread  
435 implementation of automated systems. High process variability is also cited as one of the major  
436 challenges for integrating automation into existing industrial environments (Frohm et al. 2006) and is  
437 necessary when adapting to changing market conditions (Froschauer et al. 2008). Across laboratory  
438 protocols there are process steps that are common, and it these where commercially available systems  
439 are more likely to be of assistance to the individual researcher. Liquid handling, through the  
440 manipulation of pipettes and receptacles is a one example ubiquitous to a range of molecular biology  
441 protocols, with a growing number of competing vendors offering more affordable and adaptable  
442 automation options (Barthels et al. 2020).

443 How frequently a protocol is likely to be used over time is also a key factor when considering  
444 automation. A protocol developed for a specific project may only be used in a single laboratory for a  
445 short period, negating the long-term benefits that automation could provide. On occasion a researcher  
446 may find that their new protocol becomes widely adopted for an extended period in their own  
447 laboratory, and possibly throughout other laboratories too. In this scenario automation becomes a  
448 more attractive option and is not always driven by the original founding laboratory. Sequencing, is  
449 one example where the initial manual protocol developed by Sanger and colleagues (Sanger et al.  
450 1977) was eventually automated by researchers at different institutions (García-Sancho 2007).

## 451 **5.6 Labware and consumables**

452 Automation equipment operates most effectively when input materials or consumables are  
453 standardised. In the case of standard shaped labware this allows non-adaptive, rigid automation  
454 components such as grippers to gain full custody of the device, allowing greater accuracy of  
455 placement and potentially faster actuations. Currently there remains a large amount of variation in  
456 labware not only between research laboratories but also within the same laboratory. The variant a  
457 researcher uses can change frequently based upon cost, availability or personal preference.  
458 Disposable plastics are an example where different manufacturers produce products that are, from an  
459 experimental, viewpoint functionally identical but with variations in the products dimensions and  
460 materials. The justification for these variants maybe a small improvement in handling, or simply to  
461 circumvent intellectual property assigned to a competing product. These present a significant  
462 challenge to automated handling equipment where even small variations, that are unnoticeable when  
463 handled manually, can render an automated system using non-adaptive handling elements useless.  
464 Clinical laboratories negate this issue by utilising standardised plastics for sample collections that can  
465 then be more readily processed autonomously. The recent advent of soft robotics may provide  
466 solutions to these challenges where rigid handling systems are replaced with pliable, adaptive designs  
467 sometimes based upon biomimetic examples (Noel and Hu 2018).

468 A counterstrategy to labware variation has emerged from commercial developers of automation.  
469 Unfortunately, the solution is often combined with a sales strategy aimed at securing a continuous  
470 revenue stream following the sale of the initial capital equipment. Commercially available systems  
471 are frequently designed in a fashion such that automation systems can only operate with specific  
472 consumables, available for purchase from themselves or a licensed distributor (Moutsatsou et al.  
473 2019; Huggett et al. 2009). Examples include the pipette tips for the Opentrons and Tecan EVO  
474 liquid dispensing systems, array tape for Douglas Scientific's IntelliQube PCR system, purification  
475 cards for Invitrogens benchpro and spin kits for Qiagens Qiacube system. A laboratory binding  
476 themselves to a single consumable supplier has little or no guarantee of future price stability or even  
477 long-term supply should the commercial vendor cease to exist. Committing to a long-term, single

478 vendor, supply chain is considered a very unwise strategy in a commercial context but is a  
479 worryingly frequent arrangement for automation equipment available to research laboratories.

480 There are two competing forces for labware standardisation; top-down and bottom up pressure,  
481 outlined in figure 3. Top-down pressure, as described above, is where commercial automation  
482 organisations seek to dominate a section of the market by forcing users to purchase specific labware  
483 through the sale of inflexible hardware. Bottom-up pressure acts in the opposite direction, when  
484 manufacturers of labware and laboratories slowly gravitate towards one standard form that  
485 automation developers are then forced to adopt. An example where bottom-up pressure has  
486 succeeded is in the largely standardised external dimensions of well plates, the ANSI/SLAS standard  
487 (Society for Laboratory Automation and Screening 2011), that has enabled automation of microscopy  
488 and plate reading procedures (McClymont and Freemont 2017). The range of automation equipment  
489 available for standard well plates is correspondingly larger, increasing competition, reducing running  
490 costs and making automation more affordable. There is likely to be a reciprocal benefit for labware  
491 manufacturers too, with an associated increase in demand for consumables. More instances of  
492 labware standardisation would allow a wider range of protocols to be automated.

### 493 **5.7 Environment impact**

494 The environmental impact that an item of equipment can have throughout its entire lifespan, from  
495 manufacture, to usage, to end-of-life disposal and recycling is an important consideration for many  
496 research institutions. A particular concern for laboratories is the rate at which automation consumes  
497 disposable plastics. Research institutions produce a large amount of plastic waste, estimated at 5.5  
498 million tonnes annually (Urbina et al. 2015), primarily to avoid contamination between samples.  
499 Commitments to minimising their use are part of a growing trend where laboratories aim to switch to  
500 recyclable or reusable alternatives (Bistulfi 2013; Krause et al. 2020). Automation designed around  
501 the same single-use plastic principle can generate even greater volumes of waste than human  
502 operators, due to higher experimental throughputs (Howes 2019). These designs are incompatible  
503 with research organisations who are committed to minimising their environmental impact. The  
504 consideration given to environmental concerns is currently very low or non-existent in many  
505 commercially available laboratory automation systems. An exception is Grenova’s pipette washing  
506 systems (Safavi and Anderson 2019) that can be integrated into existing automated liquid dispensing  
507 units. It is hoped that this type of equipment represents an emerging category of environmentally  
508 focused automation that will become ever more important to laboratories in the future.

### 509 **5.8 Culture**

510 There exists a fundamental culture difference between an academic research laboratory and the  
511 industrial workplace environment, that can inhibit investment in automation. It is hoped that the  
512 majority of principal investigators view their laboratory as a platform for staff and students to  
513 increase their skills and experience before they move onwards in their careers. This is a crucial  
514 “people” output that accompanies the research output of a laboratory usually measured in scientific  
515 discoveries and publications. Although many companies also place a high-value on workforce  
516 upskilling their focus is primarily on profit and not on being a training institution to allow employee  
517 progression elsewhere. Consequently, many will favour investment in equipment over staff if a  
518 business case can be made (Rampell 2011). An academic principal investigator however, is likely to  
519 preferentially invest in additional people rather than equipment, with funding schemes frequently  
520 weighted this way too. Money spent on a large item of automation equipment could, for example, pay  
521 for several post-doctoral researchers or fund multiple PhD projects. In the context of automation this  
522 culture could be described as a form of benevolent Luddism.

523 The availability and culture of undergraduate labour may also be inhibiting investment in laboratory  
524 automation. Undergraduates working in laboratories contribute by performing experiments that can  
525 generate preliminary data for grant applications or for publications. The benefits to the student reside  
526 in the acquisition of experience and skills that can enhance their employability prospects upon  
527 completion of their studies (Seeling and Choudhary 2016). This reciprocal arrangement and the high  
528 availability of undergraduates provides a means for carrying out labour intensive laboratory tasks.  
529 Not all principal investigators will view this relationship in such a cold manner, and will  
530 considerably assign duties that can generate useful data whilst simultaneously teaching students both  
531 the basics and realities of research. Unfortunately, there is evidence that some less altruistic  
532 supervisors do assign undergraduates to tasks that require a high degree of repetition (Hayward et al.  
533 2017). These are likely to be precisely the type of tasks where automation can be effectively applied.

## 534 **6 The laboratory automation interim technology gap**

535 It is interesting to compare the relatively recent development of manual labour-saving laboratory  
536 automation equipment with other older, more mature automation processes. Here we refer to  
537 equipment that replaces manual human manipulation rather than machinery that performs operations  
538 operators are physically incapable of executing, such as centrifuging. Taking the millennia-old  
539 example of sewing, with just a needle, thread and cloth it is possible, given time, for a skilled human  
540 operator to create a garment. Equally the same items can be completely mechanised with expensive,  
541 high-level automation equipment and the garment produced with no human input necessary beyond  
542 the need to turn the machine on. Comparing with the laboratory process of cell culture which  
543 requires, media, pipettes, labware and some starting cells a skilled operator can also, given time,  
544 passage cells and create a sub-culture for experimentation. Again, the same output can also be  
545 produced using an entirely automated, costly, high-level system, with minimal operator input.  
546 However, in the case of needlework there exists a range of lower cost interim labour-saving  
547 automation options between these two extremes, such as motor driven stitching machinery, or  
548 manually powered mechanisms, exemplified in the Singer sewing machine (McLoughlin and  
549 Mitchell 2013). This is not currently the case for cell culture, there are no examples of commercially  
550 available low-cost machinery (Figure 4).

551 Interim automation can arise in several scenarios. More commonly it occurs incrementally over time,  
552 as technological advances permit a shift from simple to complex machinery. Alternatively, on  
553 occasion a high-end complex automation system may be simplified due to new demands, such as an  
554 economic demand for cheaper equipment. For many laboratory automation processes there has been  
555 a rapid leap from simple to complex with, as yet, little or no development of lower cost automation  
556 technology. We believe this is due in part to the reasonable desire for academic laboratories and  
557 companies to be seen to be developing equipment at the forefront of technology. In simple terms,  
558 low-cost interim automation that removes some but not all of the manual labour from a protocol is  
559 not fashionable enough. It is unlikely to lead to a prestigious journal publication and, for commercial  
560 organisations, will not lead to financial rewards, with likely low sales volumes and low profit  
561 margins. There are therefore few incentives for academic and commercial automation developers to  
562 design such equipment.

## 563 **7 In-house laboratory automation**

564 Despite the hurdles facing researchers wishing to automate elements of their experimental  
565 procedures, there are many examples where laboratory automation development is carried out “in-  
566 house”, without the assistance of a commercial partner [or a large automation dedicated funding grant](#).  
567 Research teams are recognising that their protocols could be made more efficient by including

568 automation but find themselves restricted financially and functionally by commercially available  
569 options (Pilizota and Yang 2018). A range of ingenious methods have been developed to build low-  
570 cost automation solutions, including the integration of Lego into microscopy automation (Almada et  
571 al. 2019), microfluidics for DNA assembly (Shih et al. 2015) and rapid synthesis and testing of small  
572 molecule libraries (Baranczak et al. 2017). Laboratories with novel protocols that are nearly but not  
573 quite suited to existing automation equipment have been able to successfully upgrade commercially  
574 available systems for their specific needs (Zhang et al. 2016; McGraw et al. 2014; Konczal and Gray  
575 2017; Richter et al. 2015; Crombie et al. 2017). Repurposing existing equipment in this fashion either  
576 through software or hardware modification is a cost-and time-efficient method of obtaining higher  
577 levels of protocol automation without the arduous task of designing and building an entirely novel  
578 system. The number of automation development tools, components and virtual training options  
579 available to research laboratories continues to broaden, increasing their capability to develop low-  
580 cost solutions to labour intensive processes. The advent of affordable 3D printing modalities (Capel  
581 et al. 2018; Zluhan et al. 2016; R. Jones et al. 2011), off the shelf actuators and readily programable  
582 microcontrollers (Kim et al. 2015; Wong et al. 2018; Mabbott 2014) has given research laboratories  
583 the ability to produce componentry that can then be assembled, controlled and automated all for a  
584 relatively low cost (Barthels et al. 2020; Courtemanche et al. 2018; Needs et al. 2019). Open source  
585 designs and software have an important enabling effect for researchers who may not have  
586 engineering or programming expertise. Researchers are also able to exploit the growing market for  
587 second hand laboratory automation equipment (Zluhan et al. 2016), a case of one lab's trash is  
588 another labs treasure. Developing automation internally, whilst often cheaper, and potentially a more  
589 rewarding and enjoyable process (Pilizota and Yang 2018) can however require a substantial  
590 investment in time (May 2019). That laboratories are frequently forced into developing their own  
591 systems is an indication of the paucity of commercially available options. Existing automation  
592 developers see an insufficient market for providing their services and expertise to develop bespoke  
593 items for individual laboratories and will be justifiably reluctant to provide open source solutions that  
594 may compromise their intellectual property.

## 595 **8 Remedies**

596 Increasing the quantity and quality of laboratory automation within the research laboratory will  
597 require a concerted effort from funders, research institutions, automation developers and researchers  
598 themselves. The desire to automate elements of laboratory protocols exists. Researchers and their  
599 governmental funders (Reeves et al. 2019) collectively recognise that mechanisation can improve  
600 reproducibility and efficiency. When attempting to develop laboratory automation three interrelated  
601 components are needed for success. Connecting researchers with automation needs to automation  
602 engineers, financing the resulting collaboration, and ensuring the resulting design meets the needs.

### 603 **8.1 Collaboration**

604 Encouraging academic researchers to engage and collaborate with industrial organisations has been a  
605 long-standing objective for their host institutions. Such joint enterprises are hindered by the  
606 significant differences in culture and attitudes to one another (Berman 2008) which are in part due to  
607 each partner having different timescales and expectations from projects. Academics build projects  
608 slowly through the funding stages and ultimately desire experimental data that can be packaged into  
609 publications. Industry often likes to move more quickly and would like intellectual property that can  
610 be reconstituted into a commercial opportunity (Lynch 2016). Contrary to widespread belief these  
611 viewpoints are, however, not always the most prominent motivations for collaboration, with altruistic  
612 aims also prevalent in both parties (Berman 2008).

613 Automation engineers and life science researchers operate in markedly different disciplines and in  
614 different work environments, rarely occupying the same space to share problems and ideas. Events  
615 where these disparate groups can be brought together would allow new ideas and projects to develop,  
616 in a similar fashion to academic conferences encouraging collaboration between different  
617 laboratories. Automation engagement events that feature all levels of employees from both sides of  
618 the divide would have the greatest effect. Interaction between industrial managers and academic  
619 supervisors as well as researchers who are researching and engineers who are engineering could  
620 allow the development of solutions to everyday automation challenges in the laboratory.

621 Collaboration can also be an internal academic arrangement. Life science laboratories often have a  
622 source of automation engineering expertise within their own institution in the form of engineering  
623 faculties. Both disciplines could benefit from increased interaction and discussion around laboratory  
624 automation, with examples of collaborating biomedicine and engineering departments producing  
625 innovative automated equipment (Kane et al. 2019; Kato et al. 2010). Collaboration at an educational  
626 level can be beneficial too. Allowing undergraduate engineering students to undertake projects based  
627 upon automating a protocol within a laboratory would provide the host laboratory with designs and  
628 automation aids. Interdepartmental, interdisciplinary collaborations can bring benefits for students  
629 too, providing real world problems to develop their skills and the opportunity to apply theoretical  
630 knowledge (Wilson and Zamberlan 2012).

631 More varied career paths that allow employees with experience of industry-based automation to work  
632 in research environments can also develop new ideas that lead to mechanised laboratory equipment.  
633 Academic and industrial career paths diverge at early career stage and rarely reconnect. The majority  
634 of professional individuals progress from an academic institution into an industrial or commercial  
635 organisation. Researchers typically remain within a university environment accruing the required  
636 qualifications and experience as their career progresses. Reverse flow of employees, where an  
637 individual moves from industry to academia is less common (Bonner 2006). Encouraging a greater  
638 level of employees with experience of automation to work within life science laboratories will  
639 promote an exchange of ideas that can lead to experimental mechanisation. Such employee  
640 exchanges need not be permanent and can be sabbatical-style placements targeted at a specific  
641 project. The Knowledge Transfer Partnership is one successful long-running academic-industry  
642 exchange scheme in the authors host country that allows an employee to concurrently work on a  
643 project at both an academic and industrial organisation (Howlett 2010). These types of employee  
644 arrangements have a further benefit in deepening the relationships between Universities and  
645 industrial organisations. Academic institutions that can successfully foster relationships with  
646 industrial partners can reap substantial rewards not only in the form of publications and possible  
647 financial licencing agreements but greater reproducibility too (Edwards 2016). In a notable success  
648 story, automated sequencing technology, now the mainstay of genetic research, was successfully  
649 developed at Caltech, a research organisation with strong links to industry (García-Sancho 2007).  
650 Ultimately though any collaboration, regardless of the method of inception, is unlikely to succeed or  
651 even be embarked upon unless both partners are confident that they have the financial resources to  
652 proceed.

## 653 **8.2 Funding**

654 Greater implementation of automation can bestow benefits to funding organisations. Devoting  
655 financial resources towards automation engineering may seem paradoxical where the long-term  
656 objectives are targeted towards developing therapeutic interventions for biological diseases.  
657 However, the reproducibility of published research is essential for research financed by these



658 organisations. Automation is a critical component in driving upwards the reproducibility of  
659 disseminated research (Winder 2019). In addition, as research confidence increases in a particular  
660 therapy consideration will eventually need to shift towards how the technology can be produced in  
661 sufficient quantities and at an affordable price so that it is available to the greatest range of patients.  
662 As previously discussed, including automation at earlier stage in the development process can help in  
663 attaining these goals, easing the transition from the experimentation phase to clinical usage.  
664 Competitive schemes, where funds are specifically made available for developing laboratory  
665 automation would be beneficial in bridging the distance between the lab bench and the bedside.

666 Automation can provide benefits too for governments funding academic institutions. Increasing the  
667 level of automation across workplaces is acknowledged as strategy for economic progress (Reeves et  
668 al. 2019; Velásquez et al. 2009) with research laboratories being no exception. Access to higher  
669 levels of automation increases the output of research laboratories that exist in publicly funded  
670 institutions. Any associated automation dividend will also require appropriately skilled technical staff  
671 to maintain, operate and enhance laboratory equipment. A greater range of dedicated grant schemes  
672 specifically targeted at developing laboratory automation will, in the long-term, increase the  
673 effectiveness of all research funding.

### 674 **8.3 Laboratory automation design**

675 Improvements can be made in automation design, how it is implemented in laboratories and the range  
676 of available automations options. A large amount of laboratory automation is based upon an  
677 anthropomorphic design framework that mimics human movement. Expensive laboratory equipment  
678 frequently features an over reliance on robotics to manipulate tooling, reagents and labware in a  
679 similar manner to how researchers would themselves. These types of designs can present as being  
680 visually high-tech and impressive and there is indeed an advantage to machinery that presents as  
681 more human-like in that it is more likely to be trusted by human operators (de Visser et al. 2016).  
682 Unfortunately for many applications these designs are not always the most efficient means for  
683 automating a laboratory protocol. Robotic actuators featuring multiple axes and large operating  
684 envelopes also require even larger guarding enclosures and correspondingly complex control systems  
685 (Yachie and Natsume 2017). These design attributes render such equipment spatially and  
686 economically unsuitable for the majority of research laboratories. McClymont and Freemont provide  
687 an example where an assay requiring liquid handling can be more effectively processed and  
688 multiplexed with tooling that is not based upon an anthropomorphic design (McClymont and  
689 Freemont 2017). Hollow fibre cell culture systems are further examples of automation systems that  
690 have successfully eschewed more traditional anthropomorphic designs (Eghbali et al. 2016).

691 Designing for flexibility is also an important factor for laboratories where there is a high level of  
692 protocol variation. Laboratory automations systems designs that anticipate future scientific  
693 developments and allow for subsequent adaptation will be less likely to become prematurely obsolete  
694 and thus more valuable to research laboratories. Machinery based upon modular based design is one  
695 approach to a flexible system. Modular automation systems can allow selective matching of  
696 automation to the protocol requirements, minimising the purchase of redundant features, and also  
697 providing the option for future upgrades should it be needed. There are indications that laboratory  
698 automation developers are becoming more aware of the need for flexibility. The ongoing  
699 development of technology such as Formulatrix's rover system is one example where microwell  
700 plates are autonomously transferred between processing modules in a novel reworking of the robotic  
701 warehouse concept (Wikholm and Lindblom 2019).

702 The capability for an automation system to be modified without specialist engineering knowledge is  
703 desirable too. Allowing researchers to automate a wider range of process steps without the need for  
704 time consuming and expensive tooling redesign or extensive software reprogramming. An interesting  
705 extension of the modular design approach is to unify existing automation equipment so that it capable  
706 of performing the desired protocol in one continuous process stream. The recent development of  
707 software by the company Synthace that is capable of communicating and linking robotics from  
708 different manufacturers is one promising system for laboratories requiring highly flexible systems  
709 (Jessop-Fabre and Sonnenschein 2019; Sadowski et al. 2016).

710 To reduce the manual labour burden on laboratory research staff and students there is a need for a  
711 broader range of automation equipment. These designs should target the identified gap in labour  
712 saving automation with a focus on reducing price and footprint. In this regard employing multi axis  
713 robotics may not be the most optimal design solution and developers should be prepared to explore  
714 more cost-effective, low-tech routes to protocol automation, even if seems like a less fashionable  
715 option.

## 716 **9 The future of laboratory automation**

717 It is with a certain degree of trepidation that we follow in the footsteps of others and attempt to  
718 predict the future of laboratory automation. The life science research laboratory of the future will  
719 undoubtedly feature more automation equipment. How quickly automation is adopted will in all  
720 probability be slower than many would like and haphazard, with some fields being more suitable than  
721 others. Many of the obstacles to laboratory automation ingress we have described are long-standing  
722 and hardwired into the working practices of academic research. In particular financial hurdles faced  
723 by individual principal investigators are unlikely to be resolved and overcome in the immediate  
724 future. Bespoke, high-level automation solutions will remain beyond the reach of all but the most  
725 monied laboratories for a considerable time. Greater progress can be anticipated in the design and  
726 price of lower-level automation equipment. It is reasonable to assume that like other technologies  
727 laboratory automation will continue to mature with falling prices and more user centred designs.  
728 Hopefully incorporating more flexibility in response to consumer demand. In part this progression is  
729 already underway, with promising releases of low-cost liquid handling platforms and ongoing  
730 development of modular systems. The demand from research laboratories for automation that seeks  
731 to limit its impact on the environment will grow considerably and it is hoped that developers will  
732 create and adapt their designs to meet this need. Life science researchers will also continue to  
733 develop their own homemade laboratory automation and repurpose existing equipment, encouraging  
734 other laboratories to also take the leap into engineering. We predict that the second hand market will  
735 become an important resource for those choosing this route to automation.

736 Access to pooled resource, high-level, automation in the form of academic biofoundries is increasing  
737 and will continue to do so with expansion of existing facilities and the foundation of new ones. The  
738 outsourcing of protocols to commercial cloud laboratories has been predicted to become  
739 commonplace for a huge range of life science laboratories. From the perspective of the lab bench we  
740 are more circumspect in regards to the impact these organisations will have on day to day  
741 experimental research, with experimental range and flexibility key issues. Ultimately however, the  
742 marketplace laws of supply and demand will dictate the success rate of these enterprises.

743 An appreciation of the limitations of automation both generally and for items of specific equipment is  
744 needed from academic, commercial and funding organisations and individuals. Of all the limitations  
745 discussed in this review we wish to particularly highlight the danger of innovation inhibition.  
746 Innovation in the laboratory is essential and the freedom to tinker and create new protocols needs to

747 be retained if research is to retain a high degree of novelty. Ensuring that automation remains  
748 compatible with the curiously minded researcher will be a significant challenge for our field in the  
749 future.

750 In response to automation ingress the skills of life science researchers will need to adapt. The  
751 presence of more automation equipment will require more engineering type-skills to ensure correct  
752 equipment operation and implementation of protocols, along with a working knowledge of the  
753 biology under experimentation. Researchers will therefore need both biology “wet” skills and “dry”  
754 automation skills; such people have been imaginatively titled amphibious researchers by  
755 Mellingwood (Mellingwood 2018). It is therefore likely that automation will spawn a new generation  
756 of researchers with a range of interdisciplinary skills.

757 In summary, automation in life science laboratories lags behind its industrial and clinical counterparts  
758 due to an array of inhibiting factors, including financial, spatial and cultural challenges. Those who  
759 are able to surmount these barriers and integrate automation into their everyday protocols can reap  
760 significant reproducibility and efficiency benefits. It is essential that future laboratory automation  
761 systems are designed for flexibility to permit adaptation for changing laboratory needs and prevent  
762 the stifling of protocol innovation. A wider range of affordable bench top and remote automation  
763 options will steadily increase the ubiquity of mechanisation in life science research. Such progressive  
764 adoption of automation will emphasise the already growing interdisciplinary nature of research  
765 further blurring the boundary between science and engineering.

## 766 **10 Conflict of Interest**

767 The authors declare that the research was conducted in the absence of any commercial or financial  
768 relationships that could be construed as a potential conflict of interest. JD is a member of the Free  
769 Software Foundation, which campaigns for free (open-source) software in place of proprietary.

## 770 **11 Funding**

771 The authors would like to acknowledge support from the Biotechnology and Biological Sciences  
772 Research Council (BBSRC: grant code BB/M018040/1).

## 773 **12 Acknowledgments**

774 We would like to thank Sara Gómez Arnaiz and Fokion Glykofrydis for their feedback and  
775 discussion of the manuscript.

## 776 **13 References**

777 Abramo, G., and D’Angelo, C. (2014). How Do You Define and Measure Research Productivity?  
778 *Scientometrics* 101 (2): 1129–44. doi.org/10.1007/s11192-014-1269-8.

779 Adams, J.U. (2004). How to Negotiate for Academic Lab Space. *Scientist* 18 (16): 42–43.

780 Almada, P, Pereira, P.M., Culley, S., Caillol, G., Boroni-Rueda, F., Dix, C.L., et al. (2019).  
781 Automating Multimodal Microscopy with NanoJ-Fluidics. *Nature Communications* 10 (1): 1223.  
782 doi.org/10.1038/s41467-019-09231-9.

783 Almeida, M., and Ferreira, R. (2017). Taking Biotech to the Next Level with Laboratory Automation.  
784 Labiotech, 2017. <https://www.labiotech.eu/features/biotech-laboratory-automation/>.

- 785 Archetti, C., Montanelli, A., Finazzi, D., Caimi, L., and Garrafa, E. (2017). Clinical Laboratory  
786 Automation: A Case Study. *Journal of Public Health Research* 6 (1): 3–5.  
787 doi.org/10.4081/jphr.2017.881.
- 788 Archibald, P.R.T., Chandra, A., Thomas, D., Chose, O., Massouridès, E., Laâbi, Y., and Williams,  
789 D.J. (2016). Comparability of Automated Human Induced Pluripotent Stem Cell Culture: A Pilot  
790 Study. *Bioprocess and Biosystems Engineering* 39 (12): 1847–58. doi.org/10.1007/s00449-016-  
791 1659-9.
- 792 Autor, D.H. (2015). Why Are There Still So Many Jobs? The History and Future of Workplace  
793 Automation. *Journal of Economic Perspectives* 29 (3): 3–30. doi.org/10.1257/jep.29.3.3.
- 794 Baker, M. (2016). 1,500 Scientists Lift the Lid on Reproducibility. *Nature* 533 (7604): 452–54.  
795 doi.org/10.1038/533452a.
- 796 Baranczak, A., Tu, N.P., Marjanovic, J., Searle, P.A., Vasudevan, A., and Djuric, S.W. (2017).  
797 Integrated Platform for Expedited Synthesis-Purification-Testing of Small Molecule Libraries. *ACS*  
798 *Medicinal Chemistry Letters* 8 (4): 461–65. doi.org/10.1021/acsmedchemlett.7b00054.
- 799 Barthels, F., Barthels, U., Schwickert, M., and Schirmeister, T. (2020). FINDUS: An Open-Source  
800 3D Printable Liquid-Handling Workstation for Laboratory Automation in Life Sciences. *SLAS*  
801 *Technology* 25 (2): 190–99. doi.org/10.1177/2472630319877374.
- 802 Begley, C.G., and Ioannidis, J.P.A. (2015). Reproducibility in Science: Improving the Standard for  
803 Basic and Preclinical Research. *Circulation Research* 116 (1): 116–26.  
804 doi.org/10.1161/CIRCRESAHA.114.303819.
- 805 Benchoufi, M., and Ravaud, P. (2017). Blockchain Technology for Improving Clinical Research  
806 Quality. *Trials* 18 (1): 1–5. doi.org/10.1186/s13063-017-2035-z.
- 807 Berman, J. (2008). Connecting with Industry: Bridging the Divide. *Journal of Higher Education*  
808 *Policy and Management* 30 (2): 165–74. doi.org/10.1080/13600800801938762.
- 809 Besteman, S.B., and Bont, L.J. (2019). Fail-Fast in Respiratory Syncytial Virus Vaccine  
810 Development. *American Journal of Respiratory and Critical Care Medicine* 200 (4): 410–12. doi.org/  
811 10.1164/rccm.201901-0233ED.
- 812 Beugelsdijk, T.J. (1991). The Future of Laboratory Automation. *Genetic Analysis: Biomolecular*  
813 *Engineering* 8 (7): 217–20. doi.org/10.1016/1050-3862(91)90016-K.
- 814 Bistulfi, G. (2013). Reduce, Reuse and Recycle Lab Waste. *Nature* 502 (7470): 170–170.  
815 doi.org/10.1038/502170a.
- 816 Björklund, M., Crenshaw A.G., Djupsjöbacka, M., and Johansson, H. (2000). Position Sense Acuity  
817 Is Diminished Following Repetitive Low-Intensity Work to Fatigue in a Simulated Occupational  
818 Setting. *European Journal of Applied Physiology* 81 (5): 361–67. doi.org/10.1007/s004210050055.
- 819 Bonner, J. (2006). Back to Academia: A Mid-Life Crisis? *New Scientist*, 2006.  
820 <https://www.newscientist.com/article/mg19125711-900-back-to-academia-a-mid-life-crisis/>.

- 821 Boyd, J. (2002). Robotic Laboratory Automation. *Science* 295 (5554): 517–18.  
822 doi.org/10.1126/science.295.5554.517.
- 823 Burger, B., Maffettone, P., Gusev, V., Aitchison, C., Bai, Y., Xiaoyan. W., Sprick. R.S, and  
824 Cooper, A.I. et al. (2020). A Mobile Robotic Researcher. *Nature* 583. doi.org/10.1038/s41586-020-  
825 2442-2.
- 826 Capel, A.J., Rimington, R.P., Lewis, M.P., and Christie, S.D.R. (2018). 3D Printing for Chemical,  
827 Pharmaceutical and Biological Applications. *Nature Reviews Chemistry* 2 (12): 422–36.  
828 doi.org/10.1038/s41570-018-0058-y.
- 829 Caragher, T.E., Lifshitz, M.S., and DeCresce, R. (2017). “Analysis: Clinical Laboratory  
830 Automation.” In *Henry’s Clinical Diagnosis and Management by Laboratory Methods*, ed by R.A  
831 McPherson and M Pincus. (Elsevier), 60-65..
- 832 Casadevall, A, and Fang F.C. (2010). Reproducible Science. *Infection and Immunity* 78 (12): 4972–  
833 75. doi.org/10.1128/IAI.00908-10.
- 834 Ceroni, J.A. (2009). “Economic Rationalization of Automation Projects.” In *Springer Handbook of*  
835 *Automation*, ed by S.Y Nof. (Springer Berlin Heidelberg). 699–713 doi.org/10.1007/978-3-540-  
836 78831-7\_40.
- 837 Chambers, S., Kitney, R., and Freemont, P. (2016). The Foundry: The DNA Synthesis and  
838 Construction Foundry at Imperial College. *Biochemical Society Transactions* 44 (3): 687–88.  
839 doi.org/10.1042/BST20160007.
- 840 Chao, R, Mishra, S., Si, T., and Zhao, H. (2017). Engineering Biological Systems Using Automated  
841 Biofoundries. *Metabolic Engineering* 42 (June): 98–108. doi.org/10.1016/j.ymben.2017.06.003.
- 842 Choi, Q., Kim, H.J., Kim, J.W., Kwon, G.C., and Koo, S.H., (2018). Manual versus Automated  
843 Streaking System in Clinical Microbiology Laboratory: Performance Evaluation of Previ Isola for  
844 Blood Culture and Body Fluid Samples. *Journal of Clinical Laboratory Analysis* 32 (5): 1–7.  
845 doi.org/10.1002/jcla.22373.
- 846 Clark, D.E., and Pickett S.D. (2000). Computational Methods for the Prediction of ‘Drug-Likeness.  
847 *Drug Discovery Today* 5 (2): 49–58. doi.org/10.1016/S1359-6446(99)01451-8.
- 848 Courtemanche, J., King, S., and Bouck, D. (2018). Engineering Novel Lab Devices Using 3D  
849 Printing and Microcontrollers. *SLAS Technology* 23 (5): 448–55.  
850 doi.org/10.1177/2472630318766858.
- 851 Crombie, D.E., Daniszewski, M., Liang, H.H., Kulkarni, T., Li, F., Lidgerwood, G.E., et al. (2017).  
852 Development of a Modular Automated System for Maintenance and Differentiation of Adherent  
853 Human Pluripotent Stem Cells. *SLAS Discovery* 22 (8): 1016–25.  
854 doi.org/10.1177/2472555217696797.
- 855 Crone, M.A., Priestman, M., Ciecionska, M., Jensen, K, Sharp, D.J., Anand, A., Randell, P., Storch,  
856 M., and Freemont, P.S. (2020). A Role for Biofoundries in Rapid Development and Validation of  
857 Automated SARS-CoV-2 Clinical Diagnostics. *Nature Communications* 11 (1): 1–11.  
858 doi.org/10.1038/s41467-020-18130-3.

- 859 Croxatto, A., Prod'hom, G., Faverjon, F., Rochais, Y., and Greub, G. (2016). Laboratory Automation  
860 in Clinical Bacteriology: What System to Choose? *Clinical Microbiology and Infection* 22 (3): 217–  
861 35. doi.org/10.1016/j.cmi.2015.09.030.
- 862 Daniszewski, M., Crombie, D.E., Henderson, R., Liang, H.H., Wong, R.C.B., Hewitt, A.W., et al.  
863 (2018). Automated Cell Culture Systems and Their Applications to Human Pluripotent Stem Cell  
864 Studies. *SLAS Technology* 23 (4): 315–25. doi.org/10.1177/2472630317712220.
- 865 Doulgkeroglou, M.N., Nubila, A., Niessing, B., König, N., Schmitt, R.H., Damen, J., Szilvassy, S.J.,  
866 et al. (2020). Automation, Monitoring, and Standardization of Cell Product Manufacturing. *Frontiers*  
867 in Bioengineering and Biotechnology 8 (July): 1–12. doi.org/10.3389/fbioe.2020.00811.
- 868 Edwards, A. (2016). Reproducibility: Team up with Industry. *Nature* 531 (7594): 299–301.  
869 doi.org/10.1038/531299a.
- 870 Eghbali, H., Nava, M.M., Mohebbi-Kalhor, D., and Raimondi, M.T. (2016). Hollow Fiber  
871 Bioreactor Technology for Tissue Engineering Applications. *International Journal of Artificial*  
872 *Organs* 39 (1): 1–15. doi.org/10.5301/ijao.5000466.
- 873 Egri, P., Csáji, B.C., Kis, K.B., Monostori, L., Váncza, J., Ochs, J., Jung, S., et al. (2020). Bio-  
874 Inspired Control of Automated Stem Cell Production. *Procedia CIRP* 88: 600–605.  
875 doi.org/10.1016/j.procir.2020.05.105.
- 876 European Commission. (2016). H2020 Programme Fact Sheets Grants 2 (December): 35.  
877 [http://ec.europa.eu/research/participants/data/ref/h2020/other/gm/h2020-grant-factsheet\\_en.pdf](http://ec.europa.eu/research/participants/data/ref/h2020/other/gm/h2020-grant-factsheet_en.pdf).
- 878 Fanelli, D. (2018). Opinion: Is Science Really Facing a Reproducibility Crisis, and Do We Need It  
879 To? *Proceedings of the National Academy of Sciences* 115 (11): 2628–31.  
880 doi.org/10.1073/pnas.1708272114.
- 881 Freedman, L.P., Cockburn, I.M., and Simcoe, T.S. (2015). The Economics of Reproducibility in  
882 Preclinical Research. *PLoS Biology* 13 (6): 1–9. doi.org/10.1371/journal.pbio.1002165.
- 883 Frohm, J., Lindström, V., Winroth, M., and Stahre, J. (2006). The Industry's View on Automation in  
884 Manufacturing. *IFAC Proceedings Volumes* 39 (4): 453–58. doi.org/10.3182/20060522-3-FR-  
885 2904.00073.
- 886 Frohm, J., Lindström, V., Winroth, M., and Stahre, J. (2008). Levels of Automation in  
887 Manufacturing. *International Journal of Ergonomics and Human Factors* 30 (3): 71–74.  
888 doi.org/10.1177/154193129503900117.
- 889 Froschauer, R., Dhungana, D., and Gruenbacher, P. (2008). Managing the Life-Cycle of Industrial  
890 Automation Systems with Product Line Variability Models. In 2008 34th Euromicro Conference  
891 Software Engineering and Advanced Applications, 35–42. IEEE. doi.org/10.1109/SEAA.2008.21.
- 892 García-Sancho, M. (2007). Sequencing As a Way of Work : A History of Its Emergence and  
893 Mechanisation – From Proteins To Dna , 1945-2000. [PhD Thesis]. [London (UK)]: Imperial College  
894 London.

- 895 Genzen, J.R., Burnham, C.A.D., Felder, R.A., Hawker, C.D., Lippi, G., and Peck Palmer, O.M.  
896 (2018). Challenges and Opportunities in Implementing Total Laboratory Automation. *Clinical*  
897 *Chemistry* 64 (2): 259–64. doi.org/10.1373/clinchem.2017.274068.
- 898 Goldblatt, E.M., and Lee, W.H. (2010). From Bench to Bedside: The Growing Use of Translational  
899 Research in Cancer Medicine. *American Journal of Translational Research* 2 (1): 1–18.
- 900 Goodman, S.N., Fanelli, D., and Ioannidis, J.P.A. (2018). What Does Research Reproducibility  
901 Mean? *Science Translational Medicine* 8 (341): 341ps12-341ps12.  
902 doi.org/10.1126/scitranslmed.aaf5027.
- 903 Greub, G, Sahli, R., Brouillet, R., and Jatou, K. (2016). Ten Years of R&D and Full Automation in  
904 Molecular Diagnosis.” *Future Microbiology* 11 (3): 403–25. doi.org/10.2217/fmb.15.152.
- 905 Groth, P, and Cox, J. (2017). Indicators for the Use of Robotic Labs in Basic Biomedical Research: A  
906 Literature Analysis. *PeerJ* 2017 (11). doi.org/10.7717/peerj.3997.
- 907 Harrison, R., Colombo, A.W., West, A.A., and Lee, S.M. (2007). Reconfigurable Modular  
908 Automation Systems for Automotive Power-Train Manufacture. *International Journal of Flexible*  
909 *Manufacturing Systems* 18 (3): 175–90. doi.org/10.1007/s10696-006-9008-y.
- 910 Hasegawa, Y. (2009). Advances in Robotics and Automation: Historical Perspectives.” In *Springer*  
911 *Handbook of Automation*, 3–4. (Springer Berlin Heidelberg.) doi.org/10.1007/978-3-540-78831-  
912 7\_1.
- 913 Hawker, C.D., Genzen, J.R., and Wittwer, C.T. (2017). Automation in the Clinical Laboratory. In  
914 *Tietz Textbook of Clinical Chemistry and Molecular Diagnostics*, Sixth Edit, 370-370.e24. (Elsevier  
915 Inc.) doi.org/10.1016/B978-0-323-35921-4.00026-0.
- 916 Hawker, C.D., and Schlank, M.R. (2000). Development of Standards for Laboratory Automation.  
917 *Clinical Chemistry* 46 (5): 746–50. doi.org/10.1093/clinchem/46.5.746.
- 918 Hawkins, R.C. (2007). Laboratory Turnaround Time. *The Clinical Biochemist. Reviews* 28 (4): 179–  
919 94. doi.org/10.1093/ajcp/105.6.676.
- 920 Hayden, E.C. (2014). The Automated Lab. *Nature* 516 (729): 131–32. doi.org/10.1038/516131a.
- 921 Hayward, C.N., Laursen S.L., and Thiry, H. (2017). Why Work with Undergraduate Researchers?  
922 Differences in Research Advisors’ Motivations and Outcomes by Career Stage. *CBE Life Sciences*  
923 *Education* 16 (1): 1–11. doi.org/10.1187/cbe.16-07-0229.
- 924 Heathman, T.R.J., Nienow, A.W., McCall, M.J., Coopman, K., Kara, B., and Hewitt, C.J. (2015).  
925 The Translation of Cell-Based Therapies: Clinical Landscape and Manufacturing Challenges.  
926 *Regenerative Medicine* 10 (1): 49–64. doi.org/10.2217/rme.14.73.
- 927 Howes, L. (2019). Can Laboratories Move Away from Single-Use Plastic? *ACS Central Science* 5  
928 (12): 1904–6. doi.org/10.1021/acscentsci.9b01249.
- 929 Howlett, R.J. (2010). Knowledge Transfer between UK Universities and Business. In *Smart*  
930 *Innovation, Systems and Technologies*, 5:1–14. doi.org/10.1007/978-3-642-14594-0\_1.

- 931 Hua, S., de Matos, M.B.C., Metselaar, J.M., and Storm, G. (2018). Current Trends and Challenges in  
932 the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development  
933 and Commercialization. *Frontiers in Pharmacology* 9 (JUL): 1–14.  
934 doi.org/10.3389/fphar.2018.00790.
- 935 Huggett, J., Green, C., and Zumla, A. (2009). Nucleic Acid Detection and Quantification in the  
936 Developing World. *Biochemical Society Transactions* 37 (2): 419–23.  
937 doi.org/10.1042/BST0370419.
- 938 Iridiastadi, H., and Nussbaum, M.A. (2006). Muscular Fatigue and Endurance During Intermittent  
939 Static Efforts: Effects of Contraction Level, Duty Cycle, and Cycle Time. *Human Factors: The*  
940 *Journal of the Human Factors and Ergonomics Society* 48 (4): 710–20.  
941 doi.org/10.1518/001872006779166389.
- 942 Jessop-Fabre, M.M., and Sonnenschein N. (2019). Improving Reproducibility in Synthetic Biology.  
943 *Frontiers in Bioengineering and Biotechnology* 7 (FEB): 1–6. doi.org/10.3389/fbioe.2019.00018.
- 944 Jones, R, Haufe, P., Sells, E., Iravani, P., Olliver, V., Palmer, C., et al. (2011). Reprap - The  
945 Replicating Rapid Prototyper. *Robotica* 29 (1 SPEC. ISSUE): 177–91.  
946 doi.org/10.1017/S026357471000069X.
- 947 Jones, S.E. (2013). *Against Technology: From the Luddites to Neo-Luddism*. Routledge.
- 948 Jossen, V., van den Bos, C., Eibl, R., and Eibl, D. (2018). Manufacturing Human Mesenchymal Stem  
949 Cells at Clinical Scale: Process and Regulatory Challenges. *Applied Microbiology and*  
950 *Biotechnology* 102 (9): 3981–94. doi.org/10.1007/s00253-018-8912-x.
- 951 Jung, S., Ochs, J., Kulik, M., König, N., and Schmitt, R.H., (2018). Highly Modular and Generic  
952 Control Software for Adaptive Cell Processing on Automated Production Platforms. *Procedia CIRP*  
953 72: 1245–50. doi.org/10.1016/j.procir.2018.03.189.
- 954 Kaber, D.B., Stoll, N., Thurow, K., Green, R.S., Kim, S.H, and Mosaly, P. (2009). Human-  
955 Automation Interaction Strategies and Models for Life Science Applications. *Human Factors and*  
956 *Ergonomics in Manufacturing* 19 (6): 601–21. doi.org/10.1002/hfm.20156.
- 957 Kane, K.I.W., Moreno, E.L., Hachi, S., Walter, M., Jarazo, J., Oliveira, M.A.P., et al. (2019).  
958 Automated Microfluidic Cell Culture of Stem Cell Derived Dopaminergic Neurons. *Scientific*  
959 *Reports* 9 (1): 1–12. doi.org/10.1038/s41598-018-34828-3.
- 960 Kato, R., Iejima, D., Agata, H., Asahina, I., Okada, K., Ueda, M., et al. (2010). A Compact,  
961 Automated Cell Culture System for Clinical Scale Cell Expansion from Primary Tissues. *Tissue*  
962 *Engineering - Part C: Methods*. doi.org/10.1089/ten.tec.2009.0305.
- 963 Katsundo, H. (1994). Automation — Its Concept and a Short History. *Technovation* 14 (2): 121–28.  
964 doi.org/10.1016/0166-4972(94)90101-5.
- 965 Kempner, M.E., and Felder, R.A. (2002). A Review of Cell Culture Automation. *JALA - Journal of*  
966 *the Association for Laboratory Automation* 7 (2): 56–62. doi.org/10.1016/S1535-5535(04)00183-2.



- 967 Khanna, R, Guler, I., and Nerkar, A. (2016). Fail Often, Fail Big, and Fail Fast? Learning from Small  
968 Failures and R&D Performance in the Pharmaceutical Industry. *Academy of Management Journal* 59  
969 (2): 436–59. doi.org/10.5465/amj.2013.1109.
- 970 Kim, K.W., Lee, M.S., Ryu, M.H., and Kim, J.W. (2015). Arduino-Based Automation of a DNA  
971 Extraction System. Edited by Wen-Hsiang Hsieh. *Technology and Health Care* 24 (s1): S105–12.  
972 doi.org/10.3233/THC-151048.
- 973 King, R.D., Rowland, J., Oliver, S.G., Young, M., Aubrey, W., Byrne, E., et al. (2009). The  
974 Automation of Science. *Science* 324 (5923): 85–89. doi.org/10.1126/science.1165620.
- 975 Kitney, R., Adeogun, M., Fujishima, Y., Goñi-Moreno, Á., Johnson, R., Maxon, M., et al. (2019).  
976 Enabling the Advanced Bioeconomy through Public Policy Supporting Biofoundries and Engineering  
977 Biology. *Trends in Biotechnology* 37 (9): 917–20. doi.org/10.1016/j.tibtech.2019.03.017.
- 978 Klaus, B., and del Alamo, D. (2018). Talent Identification at the Limits of Peer Review: An Analysis  
979 of the EMBO Postdoctoral Fellowships Selection Process. *BioRxiv*, 481655.  
980 doi.org/10.1101/481655.
- 981 Klevebring, D., Gry, M., Lindberg, J., Eidefors, A., and Lundeberg, J. (2009). Automation of CDNA  
982 Synthesis and Labelling Improves Reproducibility. *Journal of Biomedicine and Biotechnology* 2009:  
983 1–7. doi.org/10.1155/2009/396808.
- 984 Konczal, J., and Gray, C.H. (2017). Streamlining Workflow and Automation to Accelerate  
985 Laboratory Scale Protein Production. *Protein Expression and Purification* 133: 160–69.  
986 doi.org/10.1016/j.pep.2017.03.016.
- 987 Kotin, R.M. (2011). Large-Scale Recombinant Adeno-Associated Virus Production. *Human*  
988 *Molecular Genetics* 20 (1): 2–6. doi.org/10.1093/hmg/ddr141.
- 989 Krause, M., Gautam, K., and Małgorzata, A., Niraula, A.G. (2020). Reducing Plastic Waste in the  
990 Lab. *Chemistry World, 2020*. [https://www.chemistryworld.com/opinion/reducing-plastic-waste-in-](https://www.chemistryworld.com/opinion/reducing-plastic-waste-in-the-lab/4011550.article%0D)  
991 [the-lab/4011550.article%0D](https://www.chemistryworld.com/opinion/reducing-plastic-waste-in-the-lab/4011550.article%0D).
- 992 Kreiman, G., and Maunsell, J.H.R. (2011). Nine Criteria for a Measure of Scientific Output. *Frontiers*  
993 *in Computational Neuroscience* 5 (November): 1–6. doi.org/10.3389/fncom.2011.00048.
- 994 Lou, A.H., Elnenaei, M.O., Sadek I., Thompson, S., Crocker, B.D., and Nassar, B. (2016). Evaluation  
995 of the Impact of a Total Automation System in a Large Core Laboratory on Turnaround Time.  
996 *Clinical Biochemistry* 49 (16–17): 1254–58. doi.org/10.1016/j.clinbiochem.2016.08.018.
- 997 Lynch, K.L. (2016). Collaboration at the Heart of Innovation. *Clinical Chemistry* 62 (9): 1284.  
998 doi.org/10.1373/clinchem.2016.260687.
- 999 Mabbott, G.A. (2014). Teaching Electronics and Laboratory Automation Using Microcontroller  
1000 Boards. *Journal of Chemical Education* 91 (9): 1458–63. doi.org/10.1021/ed4006216.
- 1001 Maleki, F., Ovens, K., McQuillan, I., and Kusalik, A.J. (2019). Size Matters: How Sample Size  
1002 Affects the Reproducibility and Specificity of Gene Set Analysis. *Human Genomics* 13 (Suppl 1): 42.  
1003 doi.org/10.1186/s40246-019-0226-2.

- 1004 Marx, U, Schenk, F., Behrens, J., Meyr, U., Wanek, P., Zang, W., et al. (2013). Automatic  
1005 Production of Induced Pluripotent Stem Cells. *Procedia CIRP* 5: 2–6.  
1006 doi.org/10.1016/j.procir.2013.01.001.
- 1007 May, M. (2019). A DIY Approach to Automating Your Lab. *Nature* 569 (7757): 587–88.  
1008 doi.org/10.1038/d41586-019-01590-z.
- 1009 McClymont, D.W., and Freemont, P.S. (2017). With All Due Respect to Maholo, Lab Automation  
1010 Isn't Anthropomorphic. *Nature Biotechnology* 35 (4): 312–14. doi.org/10.1038/nbt.3795.
- 1011 McGraw, J., Tatipelli, V.K., Feyijinmi, O., Traore, M.C., Eangoor, P., Lane, S., and Stollar, E.J.  
1012 (2014). A Semi-Automated Method for Purification of Milligram Quantities of Proteins on the  
1013 QIAcube. *Protein Expression and Purification* 96: 48–53. doi.org/10.1016/j.pep.2014.01.014.
- 1014 McLoughlin, J., and Mitchell, A. (2013). Mechanisms of Sewing Machines. In *Joining Textiles*, 123–  
1015 48. Elsevier. doi.org/10.1533/9780857093967.1.123.
- 1016 Meldrum, D. (2000). Automation for Genomics, Part One: Preparation for Sequencing. *Genome*  
1017 *Research* 10 (8): 1081–92. doi.org/10.1101/gr.101400.
- 1018 Mellingwood, C. (2018). *Amphibious Researchers : Working with Laboratory Automation in*  
1019 *Synthetic Biology*. [PhD thesis]. [Edinburgh (UK)]: University of Edinburgh.
- 1020 Mifflin, T.E., Estey, C.A., and Felder, R.A. (2000). Robotic Automation Performs a Nested RT-PCR  
1021 Analysis for HCV without Introducing Sample Contamination. *Clinica Chimica Acta* 290 (2): 199–  
1022 211. doi.org/10.1016/S0009-8981(99)00192-8.
- 1023 Miles, B., and Lee, P.L. (2018). Achieving Reproducibility and Closed-Loop Automation in  
1024 Biological Experimentation with an IoT-Enabled Lab of the Future. *SLAS Technology* 23 (5): 432–  
1025 39. doi.org/10.1177/2472630318784506.
- 1026 Moutsatsou, P., Ochs, J., Schmitt, R.H., Hewitt, C.J., and Hanga. M.P. (2019). Automation in Cell  
1027 and Gene Therapy Manufacturing: From Past to Future. *Biotechnology Letters* 41 (11): 1245–53.  
1028 doi.org/10.1007/s10529-019-02732-z.
- 1029 Movsisyan, M., Delbeke, E.I.P., Berton, J.K.E.T., Battilocchio, C., Ley, S.V., and Stevens, C.V.  
1030 (2016). Taming Hazardous Chemistry by Continuous Flow Technology. *Chemical Society Reviews*  
1031 45 (18): 4892–4928. doi.org/10.1039/c5cs00902b.
- 1032 Munafò, M.R., Nosek, B.A., Bishop, D.V.M., Button, K.S., Chambers, C.D., Du Sert., N.P, et al.  
1033 (2017). A Manifesto for Reproducible Science. *Nature Human Behaviour* 1 (1): 1–9.  
1034 doi.org/10.1038/s41562-016-0021.
- 1035 Needs, S.H., Diep, T.T, Bull, S.P., Lindley-Decaire, A., Ray, P., and Edwards, A.D. (2019).  
1036 Exploiting Open Source 3D Printer Architecture for Laboratory Robotics to Automate High-  
1037 Throughput Time-Lapse Imaging for Analytical Microbiology. *PLoS ONE* 14 (11). doi.org/10.1371/  
1038 journal.pone.0224878.
- 1039 Noel, A.C., and Hu, D.L. (2018). The Tongue as a Gripper. *Journal of Experimental Biology* 221 (7).  
1040 doi.org/10.1242/jeb.176289.

- 1041 Ochs, J., Barry F., Schmitt, R., and Murphy, J.M. (2017). Advances in Automation for the Production  
1042 of Clinical-Grade Mesenchymal Stromal Cells: The AUTOSTEM Robotic Platform. *Cell and Gene*  
1043 *Therapy Insights* 3 (8): 739–48. doi.org/10.18609/cgti.2017.073.
- 1044 Panchalingam, K.M., Jung, S., Rosenberg, L., and Behie, L.A. (2015). Bioprocessing Strategies for  
1045 the Large-Scale Production of Human Mesenchymal Stem Cells: A Review. *Stem Cell Research &*  
1046 *Therapy* 6 (1): 225. doi.org/10.1186/s13287-015-0228-5.
- 1047 Peng, R. (2015). The Reproducibility Crisis in Science: A Statistical Counterattack. *Significance* 12  
1048 (3): 30–32. doi.org/10.1111/j.1740-9713.2015.00827.x.
- 1049 Pilizota, T., and Yang, Y.T. (2018). ‘Do It Yourself’ Microbial Cultivation Techniques for Synthetic  
1050 and Systems Biology: Cheap, Fun, and Flexible. *Frontiers in Microbiology* 9 (July): 1–9.  
1051 doi.org/10.3389/fmicb.2018.01666.
- 1052 Plebani, M. (2010). The Detection and Prevention of Errors in Laboratory Medicine. *Annals of*  
1053 *Clinical Biochemistry* 47 (2): 101–10. doi.org/10.1258/acb.2009.009222.
- 1054 Price, A.P., Godin, L.M., Domek, A., Cotter, T., D’Cunha, J., Taylor, D.A., and Panoskaltsis-  
1055 Mortari, A. (2015). Automated Decellularization of Intact, Human-Sized Lungs for Tissue  
1056 Engineering. *Tissue Engineering - Part C: Methods* 21 (1): 94–103.  
1057 doi.org/10.1089/ten.tec.2013.0756.
- 1058 Rafiq, Q.A., Twomey, K., Kulik, M., Leschke, C., O’Dea, J., Callens, S., et al. (2016). Developing an  
1059 Automated Robotic Factory for Novel Stem Cell Therapy Production. *Regenerative Medicine* 11 (4):  
1060 351–54. doi.org/10.2217/rme-2016-0040.
- 1061 Rafiq, Q.A, and Thomas, R.J. (2016). The Evolving Role of Automation in Process Development &  
1062 Manufacture of Cell & Gene-Based Therapies. *Cell and Gene Therapy Insights* 2 (4): 473–79.  
1063 doi.org/10.18609/cgti.2016.058.
- 1064 Rampell, C. (2011). Companies Spend on Equipment, Not Workers. *New York Times*, June 2011.  
1065 <https://www.nytimes.com/2011/06/10/business/10capital.html>.
- 1066 Ravazzi, P, and Villa, A. (2009). Economic Aspects of Automation. In *Springer Handbook of*  
1067 *Automation*, ed by S.Y Nof. (Springer Berlin Heidelberg) 93–116. doi.org/10.1007/978-3-540-  
1068 78831-7\_6.
- 1069 Reed, C.E., Fournier, J., Vamvoukas, N., and Koza, S.M.. (2018). Automated Preparation of MS-  
1070 Sensitive Fluorescently Labeled N-Glycans with a Commercial Pipetting Robot. *SLAS Technology*  
1071 23 (6): 550–59. doi.org/10.1177/2472630318762384.
- 1072 Reeves, R., Coaker, V., Hendry, D., Kerr, S., Kyle, P., Liddell-Grainger, I., et al (2019). Automation  
1073 and the Future of Work House of Commons Business, Energy and Industrial Strategy Committee.
- 1074 Richter, F., Scheib, U.S., Mehlhorn, J., Schubert, R., Wietek, J., Gernetzki, O., (2015). Upgrading a  
1075 Microplate Reader for Photobiology and All-Optical Experiments. *Photochemical & Photobiological*  
1076 *Sciences* 14 (2): 270–79. doi.org/10.1039/C4PP00361F.

- 1077 Roberts, M. (2017). Rural Luddism and the Makeshift Economy of the Nottinghamshire Framework  
1078 Knitters. *Social History* 42 (3): 365–98. doi.org/10.1080/03071022.2017.1327644.
- 1079 Russell, A.L., Lefavor, R.C., and Zubair, A.C. (2018). Characterization and Cost–Benefit Analysis of  
1080 Automated Bioreactor-Expanded Mesenchymal Stem Cells for Clinical Applications. *Transfusion* 58  
1081 (10): 2374–82. doi.org/10.1111/trf.14805.
- 1082 Sadowski, M.I., Grant, C., and Fell, T.S. (2016). Harnessing QbD, Programming Languages, and  
1083 Automation for Reproducible Biology. *Trends in Biotechnology* 34 (3): 214–27.  
1084 doi.org/10.1016/j.tibtech.2015.11.006.
- 1085 Safavi, A., and Anderson, T. (2019). Pipette tip washing device. U.S. Patent No US20190216290A1,  
1086 issued 2019.
- 1087 Saltelli, A., and Funtowicz, S. (2017). What Is Science’s Crisis Really About? *Futures* 91 (May): 5–  
1088 11. doi.org/10.1016/j.futures.2017.05.010.
- 1089 Salter, S.J., Cox, M.J., Turek, E.M., Calus, S.T., Cookson, W.O., Moffatt, M.F., et al. (2014).  
1090 Reagent and Laboratory Contamination Can Critically Impact Sequence-Based Microbiome  
1091 Analyses. *BMC Biology* 12 (1): 1–12. doi.org/10.1186/s12915-014-0087-z.
- 1092 Sanger, F., Nicklen, S., and Coulson, A.R. (1977). DNA Sequencing with Chain-Terminating  
1093 Inhibitors. *Proceedings of the National Academy of Sciences* 74 (12): 5463–67.  
1094 doi.org/10.1073/pnas.74.12.5463.
- 1095 Sarkozi, L., Simson, E., and Ramanathan, L. (2003). The Effects of Total Laboratory Automation on  
1096 the Management of a Clinical Chemistry Laboratory. Retrospective Analysis of 36 Years. *Clinica*  
1097 *Chimica Acta* 329 (1–2): 89–94. doi.org/10.1016/S0009-8981(03)00020-2.
- 1098 Schneider, G. (2018). Automating Drug Discovery. *Nature Reviews Drug Discovery* 17 (2): 97–113.  
1099 doi.org/10.1038/nrd.2017.232.
- 1100 Seeling, J.M., and Choudhary, M. (2016.) Professional Practices in Undergraduate Research  
1101 Programs. *Journal of Microbiology & Biology Education* 17 (2): 246–51.  
1102 doi.org/10.1128/jmbe.v17i2.982.
- 1103 Segal, M. (2019). An Operating System for the Biology Lab. *Nature* 573 (7775): S112–13.  
1104 doi.org/10.1038/d41586-019-02875-z.
- 1105 Shih, S.C.C., Goyal, G., Kim, P.W., Koutsoubelis, N., Keasling, J.D., Adams, P.D., et al. (2015). A  
1106 Versatile Microfluidic Device for Automating Synthetic Biology. *ACS Synthetic Biology* 4 (10):  
1107 1151–64. doi.org/10.1021/acssynbio.5b00062.
- 1108 Society for Laboratory Automation and Screening. (2011). ANSI SLAS 1-2004 (R2012) Footprint  
1109 Dimensions.
- 1110 Storrs, C. (2013). Set It and Forget It - A Tour of Three Systems for Automating Cell Culture. *The*  
1111 *Scientist*, 2013. <https://www.the-scientist.com/lab-tools/set-it-and-forget-it-39696>.

- 1112 Tacker, D.H., Topardo, J., Mahaffey, C., and Perrotta, P.L. (2014). Workflow Analysis Comparing  
1113 Manual and Automated Specimen Processing for Mass Spectrometry–Based Vitamin D Testing.  
1114 *Laboratory Medicine* 45 (4): 361–67. doi.org/10.1309/lmzl47en6kdodmxj.
- 1115 Thomson, R.B., and McElvania, E. (2019). Total Laboratory Automation: What Is Gained, What Is  
1116 Lost, and Who Can Afford It? *Clinics in Laboratory Medicine* 39 (3): 371–89.  
1117 doi.org/10.1016/j.cll.2019.05.002.
- 1118 Urbina, M.A., Watts, A.J.R., and Reardon, E.E. (2015). Labs Should Cut Plastic Waste Too. *Nature*  
1119 528 (7583): 479–479. doi.org/10.1038/528479c.
- 1120 Vaesen, K., and Katzav, J. (2017). How Much Would Each Researcher Receive If Competitive  
1121 Government Research Funding Were Distributed Equally among Researchers? *PLoS ONE* 12 (9): 4–  
1122 6. doi.org/10.1371/journal.pone.0183967.
- 1123 Varao-Sousa, T.L., Smilek, D., and Kingstone, A. (2018). In the Lab and in the Wild: How  
1124 Distraction and Mind Wandering Affect Attention and Memory. *Cognitive Research: Principles and*  
1125 *Implications* 3 (1): 42. doi.org/10.1186/s41235-018-0137-0.
- 1126 Velásquez, J.D., Chen, X.W., Yoon, S.W., and Ko, H.S. (2009). “Automation Statistics.” In *Springer*  
1127 *Handbook of Automation*, ed by S.Y Nof. (Springer Berlin Heidelberg) 1673–1701.  
1128 doi.org/10.1007/978-3-540-78831-7\_94.
- 1129 Visser, E.J., Monfort, S.S., McKendrick, R., Smith, M.A.B., McKnight, P.E., Krueger, F., et al.  
1130 (2016). Almost Human: Anthropomorphism Increases Trust Resilience in Cognitive Agents. *Journal*  
1131 *of Experimental Psychology: Applied* 22 (3): 331–49. doi.org/10.1037/xap0000092.
- 1132 Wajcman, J. (2017). Automation: Is It Really Different This Time? *The British Journal of Sociology*  
1133 68 (1): 119–27. doi.org/10.1111/1468-4446.12239.
- 1134 Weijden, I., Teelken, C., de Boer, M, and Drost, M. (2016). Career Satisfaction of Postdoctoral  
1135 Researchers in Relation to Their Expectations for the Future. *Higher Education* 72 (1): 25–40.  
1136 doi.org/10.1007/s10734-015-9936-0.
- 1137 White, S., Lacey, A., and Ardanaz-Badia, A., (2019). The Probability of Automation in England -  
1138 Office for National Statistics. Office for National Statistics, 1–16.  
1139 [https://www.ons.gov.uk/employmentandlabourmarket/peopleinwork/employmentandemployeetypes/  
1140 articles/theprobabilityofautomationinengland/2011and2017.](https://www.ons.gov.uk/employmentandlabourmarket/peopleinwork/employmentandemployeetypes/articles/theprobabilityofautomationinengland/2011and2017)
- 1141 Wikholm, D., and Lindblom, R. (2019). Rover-based integrated laboratory system including  
1142 autonomous mobile robots. International patent WO2019/139930, issued 2019.
- 1143 Wilke, W.W., Jones, R.N., and Sutton, L.D. (1995). Automation of Polymerase Chain Reaction  
1144 Tests. Reduction of Human Errors Leading to Contamination. *Diagnostic Microbiology and*  
1145 *Infectious Disease* 21 (4): 181–85. doi.org/10.1016/0732-8893(95)00041-8.
- 1146 Williams, K., Bilsland, E., Sparkes, A., Aubrey, W., Young, M., Soldatova, L.N., et al (2015).  
1147 Cheaper Faster Drug Development Validated by the Repositioning of Drugs against Neglected  
1148 Tropical Diseases. *Journal of the Royal Society Interface* 12 (104): 0–8.  
1149 doi.org/10.1098/rsif.2014.1289.

- 1150 Wilson, S., and Zamberlan, L. (2012). Show Me Yours: Developing A Faculty-Wide  
 1151 Interdisciplinary Initiative In Built Environment Higher Education. *Contemporary Issues in*  
 1152 *Education Research (CIER)* 5 (4): 331. doi.org/10.19030/cier.v5i4.7430.
- 1153 Winder, A. (2019). How Lab Automation Is Helping Drug Research. *European Pharmaceutical*  
 1154 *Manufacturer*, 2019. [https://www.epmmagazine.com/opinion/how-lab-automation-is-helping-drug-](https://www.epmmagazine.com/opinion/how-lab-automation-is-helping-drug-research/)  
 1155 [research/](https://www.epmmagazine.com/opinion/how-lab-automation-is-helping-drug-research/).
- 1156 Wong, B.G., Mancuso, C.P., Kiriakov, S., Bashor, C.J., and Khalil, A.S. (2018). Precise, Automated  
 1157 Control of Conditions for High-Throughput Growth of Yeast and Bacteria with EVOLVER. *Nature*  
 1158 *Biotechnology* 36 (7): 614–23. doi.org/10.1038/nbt.4151.
- 1159 Wrigley, J.D., McCall, E.J., Bannaghan, C.L., Liggins, L., Kendrick, C., Griffen, A., et al (2014).  
 1160 Cell Banking for Pharmaceutical Research. *Drug Discovery Today* 19 (10): 1518–29.  
 1161 doi.org/10.1016/j.drudis.2014.05.006.
- 1162 Xie, I.H., Wang, M.H., Carpenter, R., and Wu, H.Y. (2004). Automated Calibration of TECAN  
 1163 Genesis Liquid Handling Workstation Utilizing an Online Balance and Density Meter. *Assay and*  
 1164 *Drug Development Technologies* 2 (1): 71–80. doi.org/10.1089/154065804322966333.
- 1165 Xu, R, Zhang, C., He, F., Zhao, X., Qi, H., Zhou, P., et al. (2018). How Physical Activities Affect  
 1166 Mental Fatigue Based on EEG Energy, Connectivity, and Complexity. *Frontiers in Neurology* 9  
 1167 (October): 1–13. doi.org/10.3389/fneur.2018.00915.
- 1168 Yachie, N., and Natsume, T. (2017). Robotic Crowd Biology with Maholo LabDroids. *Nature*  
 1169 *Biotechnology* 35 (4): 310–12. doi.org/10.1038/nbt.3758.
- 1170 Zhang, C, Long, A.M., Swalm, B., Charest, K., Wang, Y., Hu, J., et al. (2016). Development of an  
 1171 Automated Mid-Scale Parallel Protein Purification System for Antibody Purification and Affinity  
 1172 Chromatography. *Protein Expression and Purification* 128: 29–35.  
 1173 doi.org/10.1016/j.pep.2016.08.005.
- 1174 Zielinski, D., Gordon, A., Zaks, B.L., and Erlich, Y. (2014). IPipet: Sample Handling Using a Tablet.  
 1175 *Nature Methods* 11 (8): 784–85. doi.org/10.1038/nmeth.3028.
- 1176 Zluhan, E., Kelly, K., LeClair, N., Wortel, D., and Moody, K. (2016). Automating HESC  
 1177 Differentiation with 3D Printing and Legacy Liquid Handling Solutions. *MethodsX* 3: 569–76.  
 1178 doi.org/10.1016/j.mex.2016.10.005.
- 1179
- 1180 **Figure 1** - Prevalence of terms “automation” or “automated” and “robot” or “robotic” within the  
 1181 titles of PubMed articles per year over the period 1970 to 2019.
- 1182 **Figure 2** – Benefits and limitations of research laboratory automation.
- 1183 **Figure 3** – Top-down and bottom-up consumable adoption pressures. Top-down pressure occurs  
 1184 when an automation developer imposes a consumable on laboratories through tooling specific design.  
 1185 Bottom-up pressure acts in the reverse direction with laboratories and automation suppliers  
 1186 coalescing behind one consumable variant that then determines the design of automation equipment.

1187 **Figure 4** - Comparison of available labour-saving automation options for the manual intensive  
 1188 processes of sewing and cell culture. Sewing has a range of interim automation options up to fully  
 1189 autonomous systems. Cell culture by contrast has only high-level automation equipment and no  
 1190 interim low-cost analogues to replace or augment manual labour.

1191 **Table 1** - Automation levels (Frohm et al. 2008) with example laboratory automation equipment and  
 1192 an indicative cost range.

1193

<i>Automation level</i>	<i>Description</i>	<i>Biology research lab example</i>	<i>Indicative cost</i>
1	Totally manual - Totally manual work, no tools are used, only the users own muscle power. E.g. The users own muscle power	Glass washing.	£0
2	Static hand tool - Manual work with support of static tool. E.g. Screwdriver	Dissection scalpel	£10 to £30
3	Flexible hand tool - Manual work with support of flexible tool. E.g. Adjustable spanner	Pipette	£100 to £200
4	Automated hand tool - Manual work with support of automated tool. E.g. Hydraulic bolt driver	Stripette and handheld dispenser.	£200 to £300
5	Static machine/workstation - Automatic work by machine that is designed for a specific task. E.g. Lathe	Centrifuge, PCR thermal cycler, spectrophotometer, gel documentation system	£500 to £60000
6	Flexible machine/workstation - Automatic work by machine that can be reconfigured for different tasks. E.g. CNC-machine	Motorised stage microscope	£70000 to £120000
7	Totally automatic - Totally automatic work, the machine solve all deviations or problems that occur by itself. E.g. Autonomous systems	Automated cell culture system, bespoke laboratory equipment E.g: Labman Formulation engine.	£100,000 to £1,000,000

1194